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Background: Achilles tendon rupture affects over 11,000 people each year in the UK, 
leading to prolonged periods away from work, sports and social activities. Traditionally, after 
a ruptured tendon, the foot and ankle is held still in a plaster cast for eight weeks or more. 
Functional bracing is an alternative treatment which allows patients to mobilise sooner, but 
there is little evidence about how it affects overall recovery.  
Objectives: To measure the Achilles Tendon Rupture Score (ATRS), quality of life, 
complications including re-rupture, and resource use in patients having non-operative 
treatment for an Achilles tendon rupture, treated with plaster cast versus functional bracing. 
Design: A pragmatic, multicentre randomised controlled trial. 
Setting: Thirty-nine NHS hospitals  
Participants: 542 adult patients treated non-operatively for an Achilles tendon rupture were 
recruited from July 2016 through May 2018. Exclusion criteria included presentation after 14 
days, previous rupture and unable to complete questionnaires. 
Interventions: 266 participants had a plaster cast applied in the position that the foot 
naturally adopts when unsupported. The cast was changed over an 8-week period to bring the 
foot up to a position allowing walking before the cast was then removed. 274 patients had a 
functional brace which also held the foot with the toes pointing down, using wedge inserts, 
therefore allowing immediate weight-bearing. The foot position was adjusted within the brace 
over the same 8-week period.  
Main outcome measures: ATRS is patient-reported and consists of 10 items assessing 
symptoms and physical activity related to the Achilles tendon to give a score between 0 and 
100 (100, best possible outcome). Secondary outcomes were: health-related quality of life, 
complications including re-rupture and resource use at 8 weeks and 3, 6 and 9 months. 
Results: Participants had a mean age of 48.7 years, were predominantly male (79%) and 
ruptured their tendon during sports (70%). Over 93% of participants completed follow-up. 
There was no statistically significant difference in the ATRS at 9 months post-injury (-1.38; 
95% CI -4.9 to 2.1). There was a statistically significant difference in the ATRS at 8 weeks 
post-injury in favour of the Functional Brace group (5.75; 95% CI 2.2 to 9.3), but not at 3 or 
6 months post-injury. Health-related quality of life showed the same pattern with a 
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statistically significant difference at 8 weeks post-injury but not at later time-points. 
Complication profiles were similar between the groups. There were 17 cases of re-rupture in 
the Plaster Cast and 13 in the Functional Brace group. There was no difference in resource 
use. 
Conclusions: This trial provides strong evidence that early weight-bearing in a functional 
brace provides similar outcomes to traditional plaster casting and is safe for patients having 
non-operative treatment of an Achilles tendon rupture. The use of functional bracing is very 
likely to be cost-effective. 
Future work: While the UKSTAR trial provides guidance with regard to the early 
management of patients, rehabilitation following an Achilles tendon rupture is prolonged and 
further research is required to define the optimal mode of rehabilitation after the initial 
cast/brace is removed. 
Study registration: Current Controlled Trials ISRCTN12726986 
Funding details: This study was funded by the NIHR Health Technology Assessment 
programme. 
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Plain English Summary 
Achilles tendon rupture affects over 11,000 people each year in the UK, leading to prolonged 
periods away from work, sports and social activities. Traditionally, after a ruptured tendon, 
the foot and ankle is held still in a plaster cast for eight weeks or more. Functional bracing is 
an alternative treatment which allows patients to mobilise sooner, but there is little evidence 
about how it affects later recovery.  
This study was to compare traditional plaster casting to functional bracing for adult patients 
with an Achilles tendon rupture. The participants reported their own recovery using the 
Achilles Tendon Rupture Score (ATRS) which consists of 10 questions about symptoms and 
physical activity, where 100 is the best possible outcome. We also recorded quality of life, 
complications including re-rupture of the tendon, and costs from both the NHS and patients’ 
perspective. 
542 patients, treated at 39 hospitals, agreed to take part and were assigned by chance to either 
plaster casting or functional bracing. Patients reported their recovery at 8 weeks and 3,6 and 9 
months.  
What did the trial find? 
Patients recovered steadily after their injury but were still not back to normal at nine months. 
The average ATRS score rose from 38/100 at 8 weeks to 73/100 at nine months. 
Patents who had the functional brace reported that their recovery was a little better at 8 weeks 
than the patients having the plaster cast, but there was no evidence of a difference after that. 
There were 17 cases of re-rupture of the Achilles tendon in the Plaster Cast group and 13 in 
the Functional Brace group. There was no evidence of a difference in costs. 
In conclusion, this study provides strong evidence that early weight-bearing in a functional 
brace provides similar outcomes to traditional plaster casting and is safe for patients having 
treatment for an Achilles tendon rupture.  
 




Background: Achilles tendon rupture affects over 11,000 people each year in the UK, 
leading to prolonged periods away from work, sports and social activities. Traditionally, after 
a ruptured tendon, the foot and ankle are immobilised in a plaster cast for eight weeks or 
more. Functional bracing is an alternative treatment which allows patients to mobilise sooner, 
but there is little evidence about how it affects overall recovery.  
Objectives: To measure the Achilles Tendon Rupture Score (ATRS), quality of life, 
complications including re-rupture, and resource use in patients having non-operative 
treatment for an acute Achilles tendon rupture, treated with plaster cast versus functional 
bracing. 
Design: A pragmatic, multicentre randomised controlled trial. 
Setting: Thirty-nine hospitals in the UK NHS 
Participants: 542 adult patients treated non-operatively for an Achilles tendon rupture were 
recruited from July 2016 through May 2018. Patients were excluded if they presented more 
14 days after their injury, had suffered a previous rupture of the same Achilles tendon, or 
were unable to complete questionnaires. 
Interventions: 266 participants were randomised to a below-knee plaster cast applied in the 
‘gravity equinus’ position, i.e. the position that the foot naturally adopts when unsupported. 
In this position, with the toes pointing down towards the floor, the ends of the ruptured 
tendon are roughly approximated. The participants were permitted to mobilise with crutches 
immediately using their toes for balance (toe-touch) but were not able to bear weight on the 
injured hindfoot. Over the first eight weeks, as the tendon was healing, the participants 
returned to the hospital and the position of the plaster cast was gradually changed until the 
foot achieved plantigrade, i.e. the foot flat to the floor. At this point the patient was permitted 
to start to bear weight in the plaster cast. The number of changes of plaster cast and the time 
to weight-bearing was left to the discretion of the treating clinician, as per their usual 
practice. The cast was removed at eight weeks. The plaster cast provided maximum 
protection for the healing tendon; specifically restricting upward movement (dorsiflexion) of 
the ankle which may stretch the healing tendon, but it did not allow the patient to bear weight 
on the foot immediately or to move their ankle. 
18 
 
274 patients were randomised to the Functional Brace group. Initially, two solid heel wedges 
(or equivalent) inserted inside the brace to replicate the ‘gravity equinus’ position of the foot. 
However, because the bottom of the brace was flat to the floor, the participant was able to 
mobilise with immediate full weight-bearing within the functional brace. The brace also 
permitted some movement at the ankle joint. The number of wedges and foot position were 
reduced over eight weeks until the patient reached plantigrade. Again, the timing of the 
removal of wedges and change in foot position were left to the discretion of the treating 
clinician, as per their usual practice. The brace was removed at eight weeks, as per routine 
clinical care. 
Outcome measures: The primary outcome measure was the Achilles Tendon Rupture Score 
(ATRS). ATRS is patient-reported and consists of 10 items assessing symptoms and physical 
activity related to the Achilles tendon to give a score between 0 and 100, where 100 is the 
best possible outcome. Secondary outcomes were health-related quality of life (EQ-5D), and 
complications including re-rupture. Outcomes were collected at 8 weeks and 3, 6 and 9 
months post injury.  
We also collected resource use from the perspective of the National Health Service (NHS) 
and personal social services (PSS). A societal perspective for costs was adopted for the 
sensitivity analysis and this included private costs incurred by trial participants and their 
families, as well as productivity losses and loss of earnings as a result of work absences. 
Results: Participants had a mean age of 48.7 years, were predominantly male (79%) and 
ruptured their tendon during sports (70%). Over 93% of participants completed follow-up.  
There was no statistically significant difference in the ATRS at 9 months post injury (-1.38; 
95% confidence interval (CI) -4.9 to 2.1). There was a statistically significant difference in 
the ATRS at 8 weeks post injury in favour of the Functional Brace group (5.75; 95% CI 2.2 
to 9.3), but not at 3 or 6 months post injury. Health-related quality of life showed the same 
pattern with a statistically significant difference at 8 weeks post injury but not at later time-
points. Complication profiles were similar between the groups. There were 17 (6.4%) cases 
of re-rupture of the tendon in the Plaster Cast group and 13 (4.7%) in the Functional Brace 
group.  
The mean direct intervention costs were £36 for the Plaster Cast group compared with £109 
for the Functional Brace group; the mean difference of £73 was statistically significant. 
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However, by 8 weeks this difference had reversed such that the mean total NHS and PSS 
costs were significantly lower in the Functional Brace group. The difference at 8 weeks post 
injury was mostly driven by the cost of extra outpatient appointments in the Plaster Cast 
group. 
The mean total NHS and PSS cost throughout the entire follow-up period was £1183 for the 
Plaster Cast group and £1018 for the Functional Brace group. Although the functional 
bracing was marginally cheaper, the mean between-group cost difference of £164 was not 
statistically significant. 
In terms of health-related quality of life, the mean quality adjusted life-year (QALY) value 
was, on average, marginally higher for the Functional Brace group amongst complete cases 
and in the sensitivity analyses, although this mean QALY difference was not statistically 
significant.  
Therefore, since the Functional Brace group incurred slightly lower costs and achieved 
slightly better quality of life over the course of the study, in health economic terms, 
functional bracing is the dominant intervention.  
Conclusions: This trial provides strong evidence that early weight-bearing in a functional 
brace provides similar outcomes to traditional plaster casting and is safe for patients having 
non-operative treatment of an Achilles tendon rupture. The use of functional bracing is very 
likely to be cost-effective. 
Future work: While the UKSTAR trial provides guidance with regard to the early 
management of patients, rehabilitation following an Achilles tendon rupture is prolonged and 
further research is required to define the optimal mode of rehabilitation after the initial 
cast/brace is removed. 
Study registration: Current Controlled Trials ISRCTN62639639 
Funding: This study was funded by the NIHR Health Technology Assessment programme. 
 
Scientific summary word count: 1050  
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1. Introduction  
1.1 Background 
The Achilles tendon is the largest tendon in the human body and transmits the powerful 
contractions of the calf muscles that are required for walking and running. When the tendon 
ruptures, it is painful and has an immediate and serious detrimental impact on daily activities 
of living 1. In the longer-term, tendon rupture results in prolonged periods off work and time 
away from sporting activity: average time away from work is between four and eight weeks 
and time away from sport is between 26 and 39 weeks 1. This results in lost income and 
restricted daily activities in the early phase and reduced physical activity, with associated 
negative health and social consequences, in the long-term. For high-level sportsmen it is 
frequently a ‘career-ending’ injury. 
 
Achilles tendon rupture affects over 11,000 people each year in the UK, and the incidence is 
increasing as the population remains more active into older age 2. It affects all age groups in a 
bi-modal distribution; with the first peak in patients aged 30-40 years and the second 60-80 
years 2. The first peak in incidence is often associated with participation in sport, such as 
football and racquet sports, whereas the second peak often occurs during normal daily 
activities such as climbing stairs 2, 3. However, all Achilles tendon ruptures are associated 
with a pre-existing ‘tendinopathy’ which is attributed to failures in the protective/regenerative 
functions which respond to repeated microscopic injury 4, 5. 
 
Historically, the main question in relation to the management of patients with a rupture of the 
Achilles tendon has been whether or not to perform a surgical repair of the tendon. In 1981, 
Nistor et al 6 designed and published the first Randomised Controlled Trial (RCT) to address 
this clinical question.; this study was followed by a series of RCTs that were pooled in a 
meta-analysis by the Cochrane review group in 2004 7. The results suggested that surgical 
repair reduced the risk of re-rupture but came with an increased cost and a greatly increased 
risk of other complications, most of which were associated with infection and wound healing. 
There was little data on functional outcome at the time of this review. More recent trials 
comparing surgical repair and non-operative treatment have found no difference in functional 
outcome 8, 9. Since surgery carries considerable costs, and carries considerable risks to the 
patient in terms of complications 7, there is an increasing trend towards non-operative 
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treatment. However, some surgeons have been reluctant to advocate non-operative treatment 
because of concerns about the lack of evidence to guide early rehabilitation for this group of 
patients 10; specifically whether functional bracing is safe and effective if the tendon is not 
surgically repaired. 
 
Traditionally, patients have been treated in plaster casts after rupture of the Achilles tendon; 
with the cast immobilising the foot and ankle while the tendon heals. 11 However, there are 
potential problems with this approach. Firstly, there is the immediate impact on mobility for a 
period of around eight weeks, affecting activities of daily life. Secondly, there are the 
complications and risks associated with prolonged immobilization: muscle atrophy, deep vein 
thrombosis (DVT) and joint stiffness 12, 13. Finally, there are the potential long-term 
consequences which include prolonged gait abnormalities, persistent calf muscle weakness 
and an inability to return to previous activity levels 14. Functional bracing, involving 
immediate, protected weight-bearing in a brace, was designed to address these issues. 
 
In patients having a surgical repair, seven RCTs 15-21 directly comparing plaster casts with 
early movement and/or weight-bearing in a ‘functional brace’ had been conducted at the time 
that the protocol was developed for the UK Study of tendo Achilles Rehabilitation 
(UKSTAR) trial. The results favour functional bracing in terms of re-rupture rate, functional 
outcome and quality of life measures. Therefore, in the first guideline (2009) produced on 
this topic, the American Academy of Orthopaedic Surgeons recommended functional bracing 
for patients having surgical repair of their tendon 22. 
 
What about patients managed non-operatively? 
Whilst there is clear guidelines for rehabilitation for patients who have a surgical repair, there 
is no clarity with regards the use of functional bracing in non-operatively managed patients. 
Does functional bracing provide improved function and quality of life if the tendon is not 
surgically repaired? Or, in the context of a tendon that has not been stitched together, does a 
plaster cast provide greater protection and therefore improved healing compared with a 
brace? Does functional bracing facilitate faster return to work and is this cost effective? Or, is 
the tendon more vulnerable to re-rupture in a brace with the subsequent risk and cost of 




At the time that UKSTAR was developed, we supplemented the 2004 Cochrane review 7 with 
an updated literature search and found that in total only 2 additional studies 23, 24 had been 
performed comparing the use of functional bracing with plaster casts for patients managed 
non-operatively following a rupture of the Achilles tendon. Both studies suggested potential 
benefits from bracing. However, the data from the studies should be interpreted with caution 
due small patient numbers (90 in total), patients having received different functional bracing 
regimes, and minimal reporting of outcomes. 
 
The gap in the evidence was recognized in the American Academy of Orthopaedic Surgeons 
Guideline 2009 22, which concluded that “For patients treated non-operatively, we are unable 
to recommend for or against the use of immediate functional bracing for patients with acute 
Achilles tendon rupture”. With the incidence of Achilles tendon rupture on the rise, and in 
light of the large personal and societal cost associated with the injury, this gap in the evidence 
is a clear priority. A Versus Arthritis (formerly known as Arthritis Research UK (ARUK)) 
multidisciplinary ‘Think Tank’ (ARUK Birmingham 2013) on tendon injuries reported that 
rehabilitation following non-operative treatment of acute Achilles tendon injury was “the top 
research priority” in this area.  
 
Since the start of the UKSTAR trial, there have been a number of small randomised trials 
investigating both the mechanistic and functional effects of early weight-bearing in a brace 
versus cast immobilisation. In terms of tendon healing, a trial of 56 patients indicated that 
healing at a molecular level may be enhanced through early mobilisation but, given the small 
number of participants, there was no difference in objective functional outcome (heel-raise 
testing in this study) 25. A second trial investigated the biomechanical properties of the 
healing tendon in patients randomised to early weightbearing versus delayed weightbearing 
26. The investigators noted that there was less tendon stiffness in the group treated with early 
weightbearing. However, in terms of functional outcomes, the authors reported no evidence 
of a difference in Achilles Tendon Rupture Score (ATRS), although they did report a 
statistically significant improvement in health-related quality of life at one year in the group 
treated with early weight-bearing 26. Another trial included forty-seven patients who were 
treated non-operatively for an acute Achilles tendon rupture. Half of the patients were treated 
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with partial weight bearing beginning on the first day of treatment and the other half with 
non-weight bearing for the first four weeks 27. The authors concluded that early weight-
bearing was ‘safe’, in terms of the incidence of re-rupture, but there was no evidence of a 
difference in functional outcome (ATRS or Physical Activity Scale) in the first 12 months 
after the rupture. Finally, another trial compared two types of cast immobilisation of the 
Achilles tendon rupture 28. Half of the patients wore a traditional cast, which restricted 
weightbearing, while the other group wore a modified cast which included a heel ‘iron’ to 
facilitate weight-bearing. The authors found no evidence of a difference in functional 
outcome (Leppilahti Score), but there were only 84 patients in the trial. One further protocol 
has been published for a larger randomised trial of 130 patients at single centre, but results 
are not yet available 29. 
1.2 Pre-pilot data 
 
Before the UKSTAR trial, we completed four phases of pilot and preparatory work to 
establish the following: 
1. External pilot study 18. We randomised 48 patients having non-operative treatment for an 
acute rupture of the Achilles tendon to either functional bracing or plaster cast. This trial 
showed that patients and clinicians had equipoise for this question and were happy to take 
part. However, the trial identified that while plaster casting was a mature intervention, the 
important facets of the complex intervention which is functional bracing were inadequately 
defined, and that this needed to be addressed before a larger trial was performed. 
2. Defining the functional bracing intervention. In keeping with MRC framework for 
developing complex interventions, our group and collaborators performed a UK survey of 
current practice, a systematic review of published rehabilitation methods, gait analysis 
experiments using different functional brace and heel wedge combinations and qualitative 
interviews to define the optimal functional bracing regime and refine the trial design. 30, 31 
The rehabilitation strategy proposed in UKSTAR was the summation of that work which 
identified: the optimal type of orthosis (brace), the optimal foot position within the orthosis 
and the duration of application of the orthosis. 
3. The acceptability and safety of this newly defined regime was tested in a further single-
centre pilot RCT and qualitative recruitment investigation (ISRCTN68273773). 
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4. To investigate the number of patients potentially eligible for UKSTAR, we performed a 
UK-wide survey of orthopaedic trauma clinicians 10. This clearly showed that clinicians were 
enthusiastic about the study and that the number of eligible patients was large enough for a 
full trial. 
1.3  Research objectives 
The primary objective is: 
To quantify and draw inferences on observed differences in ATRS between the trial 
treatment groups at nine months post injury. 
The secondary objectives are: 
1. To quantify and draw inferences on observed differences in ATRS between the trial 
treatment groups at eight weeks, three and six months post injury. 
2. To identify any differences in health-related quality of life between the trial treatment 
groups in the first nine months post injury. 
3. To determine the complication rate between the trial treatment groups in the first nine 
months post injury. 
4. To investigate, using appropriate statistical and economic analytical methods, the resource 
use, costs and comparative cost effectiveness between the trial treatment groups  in the 
nine months post injury.  
1.4 Patient and public involvement 
We have been working with and listening to the views of patients with Achilles tendon 
injuries for many years. However, as well as this informal contribution, a series of formal 
qualitative interviews with patients and clinicians were performed in the development of the 
STAR trial (ISRCTN68273773). 11 The views of patients were used to inform and refine the 
trial interventions, processes and in particular the development of the trial 
information/materials. The patient perspective was key in the development of the trial 
protocol to ensure the acceptability of the interventions and participation. 
Two of the patients who contributed during our development work, agreed to act as lay 
representatives on the Trial Management Group (TMG) and co-applicants on the research 
grant award. Mrs Richmond later had to leave the research team for personal reasons, but Mr 
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Grant attended trial management meetings throughout the trial and contributed to all trial 
process and paperwork, with particular reference to Patient Information Leaflets. Mr Grant 
will be crucially involved in the dissemination of the findings of this study to the wider 
public. He will lead in the development of any materials, leaflets, website information, to be 
used for this purpose. Mr Grant has reviewed the plain English summary section of this 
report. 
Mr Grant was supported by the Chief Investigator and the trial coordination team. He had 
peer-support from the UK Musculoskeletal Trauma Patient and Public Involvement (PPI) 
Group, hosted in Oxford. He also had access to and support from the UNTRAP 
(University/User Teaching and Research Action Partnership) network through Warwick 
University, an organisation which promotes the engagement and involvement of service users 






2. Clinical Trial Methods 
 
2.1 Summary of study design 
The UKSTAR trial was a multicentre, randomised, pragmatic, two-group superiority trial. 
Patients presenting at 39 NHS hospitals in England and Scotland with an acute, primary 
Achilles tendon rupture for non-surgical treatment were randomised 1:1 to receive either 
functional bracing or plaster cast. 
2.2 Settings and locations 
The thirty-nine NHS hospital orthopaedic or trauma clinics in England and Scotland screened 
and recruited participants for this trial were: 
 King’s College Hospital NHS Foundation Trust, London 
 Nottingham University Hospitals NHS Trust 
 Royal Berkshire Hospital, Royal Berkshire NHS Foundation Trust 
 Aberdeen Royal Infirmary, NHS Grampian 
 Ninewells Hospital and Medical School, NHS Tayside, Dundee 
 Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde 
 Pilgrim Hospital, Boston, United Lincolnshire Hospitals NHS Trust 
 University Hospital of North Tees, North Tees and Hartlepool NHS Foundation Trust, 
Stockton-on-Tees 
 Airedale NHS Foundation Trust, Keighley 
 Salisbury District Hospital, Salisbury NHS Foundation Trust 
 The Rotherham NHS Foundation Trust 
 George Eliot Hospital NHS Foundation Trust, Nuneaton 
 James Paget University Hospital NHS Foundation Trust, Great Yarmouth 
 Southampton General Hospital, University Hospital Southampton NHS Foundation 
Trust 
 Lister Hospital, East and North Herts NHS Foundation Trust 
 Royal Cornwall Hospital, Truro, Royal Cornwall Hospitals NHS Trust 
 Tunbridge Wells Hospital, Maidstone & Tunbridge Wells NHS Trust 
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 Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust 
 Derriford Hospital, University Hospitals Plymouth NHS Trust 
 Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust 
 Luton and Dunstable University Hospital 
 Salford Royal NHS Foundation Trust 
 Scunthorpe General Hospital, Northern Lincolnshire and Goole NHS Foundation 
Trust 
 Pinderfields Hospital, Mid Yorkshire NHS Trust 
 Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust 
 Worcestershire Royal Hospital, Worcester Acute Hospitals NHS Trust 
 Doncaster Royal Infirmary, Doncaster & Bassetlaw Hospitals NHS Foundation Trust 
 St Helier Hospital, Epsom and St Helier University Hospitals NHS Trust 
 St Mary’s Hospital, Imperial College Healthcare NHS Trust London 
 Raigmore Hospital, Inverness, NHS Highland 
 Whiston Hospital, Warrington, St Helens & Knowsley Teaching Hospital NHS Trust 
 Milton Keynes University Hospital NHS Foundation Trust 
 Warwick Hospital, South Warwickshire NHS Foundation Trust 
 Queen’s Hospital, Burton Hospitals NHS Foundation Trust 
 Hereford County Hospital, Wye Valley NHS Trust 
 Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust 
 John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust 
 University Hospital of South Manchester NHS Foundation Trust 
 Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust 
2.3 Participants 
2.3.1 Participant screening and eligibility 
All adult patients presenting at the trial centres with a primary (first-time) rupture of the 
Achilles tendon were screened. The patient, in conjunction with their surgeon, decided 
whether non-surgical treatment was appropriate, as per normal clinical practice. If they 
decided not to have surgery, they were potentially eligible to take part in the trial.  
2.3.2 Eligibility  
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In order that the trial findings would be generalisable to a UK-wide population, eligibility 
criteria were broad. Patients with acute rupture of the Achilles tendon were eligible if they 
met all of the inclusion criteria and none of the exclusion criteria.  
The inclusion criteria were: 
 Patient is aged 16 years or older. 
 Patient has a primary rupture of the Achilles tendon. 
 Patient has decided to have non-operative treatment. 
The exclusion criteria were: 
 Patient presented to the treating hospital more than 14 days after injury. 
 There was evidence that the patient would be unable to adhere to trial procedures or 
complete questionnaires. 
 Patient had a previous rupture of the Achilles tendon. 
The first exclusion criterion related to patients with late presentation, which is not uncommon 
after this injury. Patients who present late may have problems with chronic tendon 
lengthening irrespective of treatment and are frequently offered surgical intervention. The 
limit of 14 days since injury has been widely used to define ‘acute’ rupture.  
If a patient taking part in the study sustained a contralateral rupture during the trial period, the 
second rupture was not included in the study because the result of this intervention would not 
be independent from the first injury. However, the patient remained in the trial, with both 
previous and future data related to the initial rupture included in the final analysis. 
Screening logs were completed at recruiting centres and collected by the UKSTAR trial 
office throughout the trial to assess the main reasons for patient exclusion at each recruitment 
centre and the number of patients who were unwilling to participate. 
Members of the local research team informed the patient of the study, and carried out the 
informed consent process, baseline data collection and randomisation.   
2.4 Baseline Assessment 
Potential participants were allowed as much time as they needed to consider the trial 
information and had the opportunity to ask questions of the attending clinical team and a 
member of the research team. The trial information was delivered verbally and in writing 
detailing the exact nature of the study; the implications and constraints of the protocol; what 
29 
 
to expect as a participant; and any risks involved in taking part. It was clearly stated that the 
participant was free to withdraw from the study at any time, for any reason, without prejudice 
to future care, and with no obligation to give the reason for withdrawal. If the patient was 
happy to participate, they were asked to personally sign and date a consent form, which was 
also signed and dated by the person who obtained consent. Consent was obtained by an 
appropriately trained member of the research team who had been delegated to obtain consent 
by the local Principal Investigator 
A copy of the signed consent form was given to the participant, and one copy was sent to the 
study coordinating team in Oxford to facilitate central monitoring.  The original signed 
consent form was retained in the medical notes, and a copy was held in the Investigator Site 
File.  Consent forms were held in a secure location separately from study data.  Permission 
was obtained to inform the participant’s general practitioner (GP) of study participation. 
Consent was asked for name and contact details (including address, mobile, phone and email) 
to be collected to facilitate follow-up, data collection and reporting of results and for a copy 
of the contact details to be sent to the UKSTAR central office team in Oxford. These details 
were used by the study team to contact the participant for follow-up at the three, six and nine 
month time-points, to resolve queries, and to send a thank you letter at the end of the 
participant’s involvement in the trial. 
Permission was sought to allow access to participant data by responsible members of the 
University of Oxford or the NHS Trust for monitoring or audit of the study to ensure that 
regulations were complied with.  
Following consent, baseline data was collected and the participant was randomised. The 
treatment took place on the same visit. A Good Clinical Practice (GCP) trained member of 
the local research team oversaw the participant’s completion of the paper Baseline 
Questionnaire, which included:  
 Date, mechanism and side of injury; 
 Baseline demographics: height, weight, smoking and alcohol status, employment 
status; 
 Current medication; 
 Previous medical history: diabetes, rheumatoid arthritis, lower limb fracture, ligament, 
tendon or nerve injury to lower limb in last 12 months, arthritis, Achilles tendinopathy 
30 
 
or other relevant conditions. 
2.5 Randomisation 
Participants were randomly allocated (1:1) to either functional bracing or plaster cast using a 
computer-generated allocation sequence stratified by recruitment centre via a secure, 
centralised web-based randomisation service provided by the Oxford Clinical Trials 
Research Unit (OCTRU). The Research Associate informed the treating clinical team of 
the allocated treatment.  
Stratification by recruitment centre helped to ensure any cluster effect related to the 
recruitment centre itself was equally distributed in the trial groups. The catchment area 
was similar for all of the recruitment centres; each recruitment centre was a trauma unit 
dealing with these injuries on a daily basis. All of the recruitment centres were familiar with 
both techniques i.e. the clinical staff used both plaster casts and functional bracing on 
a regular basis as part of their routine clinical practice.   
2.6 Post randomisation withdrawals 
Participants were free to decline consent or withdraw from the trial at any time without 
prejudice and without affecting the standard of care that they received. Participants had two 
options for withdrawal: 
 To withdraw from completing further questionnaires but allow the trial team to view 
and record de-identified data that is recorded as part of the normal standard of care; 
 To withdraw wholly from the study and only permit data obtained up to the point of 
withdrawal to be included in the final analysis. 
Withdrawn participants were not replaced, as the target sample size allowed for losses to 
follow-up. 
2.7 Interventions 
Participants received their allocated treatment (plaster cast or functional bracing) following 
randomisation.  
Although the principles of application of both plaster casts and functional bracing are 
inherent in the technique, there are different types of plaster cast material and functional 
brace design. Each patient underwent the allocated intervention as specified below, but the 
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details of application and materials used for the plaster and brace were left to the discretion of 
the treating clinician, as per their usual practice. This was intended to ensure that the results 
can be generalised across the NHS.  
2.7.1 Plaster cast 
Participants randomised to Plaster Cast received a cast in the ‘gravity equinus’ position, i.e. 
the position that the foot naturally adopts when unsupported. In this position, with the toes 
pointing down towards the floor, the ends of the ruptured tendon are roughly approximated. 
Use of ultrasound to assess the approximation of the tendon ends is not routine in the NHS 10 
and was left to the discretion of the treating clinician. The participant was permitted to 
mobilise with crutches immediately using their toes for balance (toe-touch) but was advised 
not to bear weight on the injured hindfoot. Over the first eight weeks, as the tendon was 
healing, the position of the plaster cast was changed until the foot achieved plantigrade, i.e. 
the foot flat to the floor. At this point the patient was permitted to start to bear weight in the 
plaster cast. The number of changes of plaster cast and the time to weight-bearing was left to 
the discretion of the treating clinician, as per their usual practice. The cast was removed at 
eight weeks.  
The plaster cast provided maximum protection for the healing tendon; specifically restricting 
upward movement (dorsiflexion) of the ankle which may stretch the healing tendon, but it did 
not allow the patient to bear weight on the foot immediately or to move the ankle. 
2.7.2 Functional bracing 
Participants randomised to Functional Brace received a rigid brace, as opposed to a flexible 
brace 30. Initially, two solid heel wedges (or equivalent) were inserted into the brace to 
replicate the ‘gravity equinus’ position of the foot 30. The patient was able to mobilise with 
immediate full weight-bearing within the functional brace. The brace also permitted some 
movement at the ankle joint. The number of wedges and foot position were reduced over 
eight weeks until the patient reached plantigrade. Again, the timing of the removal of wedges 
and change in foot position were left to the discretion of the treating clinician, as per their 
usual practice. The brace was removed at eight weeks, as per routine clinical care. 
2.7.3 Monitoring intervention delivery and compliance 
Clinic staff recorded the participant’s treatment in clinic records as per usual practice. At the 
8 week follow-up visit research staff recorded on the 8-week trial case report form (CRF): 
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 the intervention the patient was randomised to; 
 the intervention they received; 
 the date of the 8-week follow-up appointment; 
 for participants treated in a functional brace, irrespective of their randomisation 
allocation: 
o the number of heel wedges inserted into the heel of the functional brace at 
baseline (date of treatment), and at two, four, six and eight weeks after 
treatment; 
o the number of weeks after treatment when the patient was allowed to fully 
weight bear; 
o the number of weeks after treatment when the functional bracing was 
removed; 
o the brand of functional bracing. 
 for participants treated in a plaster cast, irrespective of their randomisation allocation: 
o the number of plaster cast changes over the eight weeks since treatment; 
o the number of weeks after treatment when the patient was allowed to fully 
weight bear; 
o the number of weeks after treatment when the plaster cast was removed; 
 whether the patient switched to another intervention during the eight weeks after 
treatment, the date of switching and the reason for switching. 
 Whether the participant received treatment with venous thromboembolism (VTE) 
prophylaxis, type and duration. 
2.8 Rehabilitation 
At the patient’s 8-week clinic appointment the plaster cast or functional brace was removed, 
unless the clinical team directed otherwise. All participants were provided with the same 
standardised, written physiotherapy advice detailing the exercises they need to perform for 
rehabilitation following their injury. This standardised rehabilitation advice was based on a 
published systematic review of current rehabilitation protocols32. All the participants were 
advised to move their toes, ankle and knee joints fully within the limits of their comfort, and 
walking was encouraged. In this pragmatic trial, any other rehabilitation input beyond the 
written physiotherapy advice (including a formal referral to physiotherapy) was left to the 
discretion of the treating clinicians. A record of any rehabilitation input (type and number of 
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additional appointments) as well as other investigations or interventions was collected as part 
of the 8-week, 3-month, 6-month and 9-month follow-up questionnaires. 
2.9 Outcome measures 
2.9.1 Primary outcome 
The primary outcome measure for this study was the ATRS 33 at nine months post injury. The 
ATRS is a validated questionnaire34  which is self-reported (completed by the 
participant). It consists of 10 items assessing symptoms and physical activity 
specifically related to the Achilles tendon. It measures: strength, fatigue, stiffness, pain, 
activities of daily living, walking on uneven surfaces, walking upstairs or uphill, running, 
jumping and physical labour. Each ATRS item varies from 0 (major limitations/symptoms) 
to 10 (no limitations/symptoms) on an 11 point scale.  The final ATRS is derived from the 
sum of the 10 questions with a total possible score range between 0 and 100, where 100 is 
the best possible score. 
2.10 Secondary outcome measures 
The secondary outcome measures were: 
 The ATRS collected at eight weeks, three months and six months post injury. 
 EQ-5D; The EQ-5D-5L is a validated, generic health-related quality of life measure 
consisting of 5 dimensions each with a 5-level answer possibility and a visual 
analogue scale (VAS) 35. The EQ-5D can be used to report health-related quality of 
life in each of the five dimensions and each combination of answers can be converted 
into a health utility score where 1 represents perfect health and 0 indicates death. The 
EQ-5D VAS takes values between 0 and 100, where 0 represents worst imaginable 
health and 100 best imaginable health. It has good test-retest reliability, is simple for 
patients to use, and gives a single preference-based index value for health status that 
can be used for broader cost-effectiveness comparative purposes.  
 Complications; all complications were recorded, from the medical records at the 8 
week review and self-reported by the patient thereafter, including: re-rupture, blood 
clots/emboli, pressure areas/hindfoot pain, falls and neurological symptoms in the 
foot. The 3-, 6- and 9-month follow-up questionnaires sent to the participant included 
questions on complications. 
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2.11 Adverse events  
Adverse events (AEs) are defined as any untoward medical occurrence in a clinical trial 
subject and do not necessarily have a causal relationship with the treatment. All AEs were 
listed on the CRF for routine return to the UKSTAR central office.  
Serious adverse events are defined as any untoward and unexpected medical occurrence that:  
 results in death; 
 is life-threatening; 
 requires hospitalisation or prolongation of existing inpatients´ hospitalisation; 
 results in persistent or significant disability or incapacity; 
 is a congenital anomaly or birth defect; 
 is any other important medical condition which, although not included in the above, 
may require medical or surgical intervention to prevent one of the outcomes listed. 
All serious adverse events (SAEs) were recorded by recruitment centre staff on the trial SAE 
reporting form and emailed to a secure NHS.net account accessed only by the research team 
within 24 hours of the investigator becoming aware of them. Once received, causality and 
expectedness were confirmed by the Chief Investigator. SAEs that were deemed to be 
unexpected and related to the trial were notified to the Research Ethics Committee within 15 
days. All such events were reported to the Trial Steering Committee (TSC) and Data and 
Safety Monitoring Committee (DSMC) at their next meetings.  
Some AEs were foreseeable as part of the proposed treatment – including those which met 
the definition of “serious” as described above – and did not require reporting immediately to 
the UKSTAR central office, provided they were recorded in the ‘Complications’ section of 
the CRFs or participant questionnaires. These events were:  re-rupture, blood clots/emboli, 
pressure areas/hindfoot pain, falls and neurological symptoms in the foot. 
All participants experiencing SAEs were followed up as per protocol until the end of the trial.  
All unexpected SAEs or suspected unexpected SAEs that occurred between date of consent 
and the date of the 9-month follow-up time-point were reported. 
2.12 Blinding 
As the type of rehabilitation used was clearly visible, participants could not be blinded to 
their treatment. In addition, the treating clinician was also not blinded to the treatment but 
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took no part in the post injury assessment of the participants. The outcome data was collected 
and entered onto the trial central database via questionnaire, by a research assistant or data 
entry clerk in the trial central office to reduce the risk of assessment bias.  
2.13 Follow-up 
UKSTAR Trial office staff contacted the participants directly for follow-up at three, six and 
nine months using the contact details that had been supplied by the participant. Participants 
were contacted by post, by email or by short message text (SMS) text message according to 
their preference and, if no response was received, they were telephoned. All follow-up 
contacts and attempted contacts were logged without personal identifying details in a contact 
log. 
Participants who had supplied an email address were sent a link by email to complete an 
online questionnaire. Participants who had supplied a mobile telephone number were sent the 
same link by SMS text message. Participants who had supplied both email address and 
mobile number were sent the link via both mechanisms. If participants did not respond to any 
of these initial approaches, they were sent a reminder one week later. If there was still no 
response after a further week, the participants were sent a paper questionnaire. If the paper 
questionnaire was not returned within two weeks, UKSTAR office staff telephoned the 
participants. If the participant was uncontactable during working hours, attempts were made 
to phone them during the evening, as many participants were of working age. 
Participants who had specified that they preferred to be contacted by post, or who had not 
supplied an email address or mobile number, were sent a questionnaire in the post, and a 
second postal questionnaire if no response was received within two weeks. UKSTAR office 
staff attempted to phone the participant for follow-up if the second postal questionnaire was 
not returned within two weeks. 
DVTs, pulmonary embolisms (PEs) and re-ruptures were reported by participants through 
completion of a questionnaire, or by participants directly to the study office, or by 
recruitment centre staff after participants had returned to their recruitment centre for further 
treatment. These reports underwent validation, as follows. In the case of a patient-reported 
DVT or PE, recruitment centres were requested to complete a DVT/PE form, which detailed 
symptoms, results of any ultrasound imaging, results of any computed tomography 
pulmonary angiogram imaging, treatment received and treatment duration. In the case of a 
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patient reported re-rupture, recruitment centres were requested to provide details of diagnosis 
and treatment. If the patient underwent surgery for a re-rupture, an operation note was 
requested. All information submitted in connection with a re-rupture was reviewed by the 
Chief Investigator, blind to the treatment allocation, in order to confirm the diagnosis. 
2.14 Sample size 
The minimum clinically important difference (MCID) for the primary outcome ATRS was 8 
points. At an individual patient level, a difference of 8 points represents the ability to walk 
upstairs or run with ‘some difficulty’ versus with ‘great difficulty’. At a population level, 8 
points represents the difference between a ‘healthy patient’ and a ‘patient with a minor 
disability’ 34.  
In previous work, the standard deviation (SD) of the ATRS at nine months post injury was 20 
points 36 Assuming a likely population variability of 20, MCID value of 8 and 90% power to 
detect the selected MCID, there was a requirement of 264 total participants to be randomised. 
Allowing a margin of 20% loss of primary outcome data to include patients who would cross 
over between interventions and those lost to follow-up, led to a requirement of 330 participants. 
We intended to recruit a minimum of 330 patients from at least 22 centres over a period of 16 
months. The trial reached its primary recruitment target of 330 participants before the end of 
the proposed recruitment window and therefore the sample size was recalculated based on a 
larger population variability equivalent to a SD of 25 points following a blinded review of the 
variability by the DSMC.  As per Table 1 calculations for SD 25, MCID 8, 5% two-sided tests 
and 20% loss to follow-up 516 participants were required. The maximum number of 
participants to be recruited for the trial was set at 550.  
 




2.15 Statistical analysis  
2.15.1 Software employed 
All analyses outlined here were undertaken using Stata version 15.0 (StataCorp, College 
Station, TX). 
2.15.2 Blinded analysis 
The distribution of variables, missing data distributions and outliers was assessed as part of a 
blinded analysis of data (not separated by treatment group) prior to the final data lock. This 
analysis was also used to help identify key prognostic variables to be included in the adjusted 
analysis. The treatment code was added to the database after the data cleaning had been 
completed and all subsequent analyses described were conducted on an unblinded dataset. The 
Statistical Analysis Plan was updated to incorporate necessary changes.   
2.15.3 Data validation 
To ensure consistency, validation checks of the data were conducted. This included checking 
for duplicate records, checking the range of variable values or missing items and validating 
potential outliers by comparing with CRFs and referring back to recruitment centres when 
necessary. Calculations for derived variables such as the ATRS were checked by hand 
calculations on 20 randomly selected participants from the dataset. These checks confirmed 
that the data had been imported into the statistical software correctly, calculation of derived 
variables had been performed correctly and merging of different data to form an analysis 
dataset was verified.  
2.15.4 Study populations 
Two populations were considered for analysis, the intention-to-treat (ITT) population and the 
Complier Average Causal Effect (CACE) population 37. The ITT population included all 
participants in their randomised groups and the CACE population included all randomised 
participants compliant with treatment. Participants were considered compliant with the 
intervention if they wore their allocated treatment for a period of six weeks or more without 
any change of treatment within this period.   
2.15.5 Descriptive analysis 
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All available data from both treatment groups (Functional Brace and Plaster Cast) was used in 
descriptive analysis.  The flow of participants through each stage of the trial, including numbers 
of participants eligible for randomisation, those randomised, receiving intended treatment, 
completing the study protocol, and analysed for the primary outcome was assessed. Reporting 
of the results was in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) for Patient Reported Outcomes (PRO) statement using the extension for non-
pharmacologic treatment interventions and patient reported outcomes 38. Any protocol 
deviations and violations were investigated. 
Participant baseline characteristics were reported by treatment group and overall, and included 
recruitment centre stratification, demographic variables age, gender, side of injury and 
mechanism of injury, body mass index (BMI), smoking status, alcohol consumption, 
medication, diagnoses, employment status and baseline values for ATRS and EQ-5D-5L before 
and after the injury.  Numbers (with percentages) for categorical variables and mean (and SD), 
or medians (with interquartile range (IQR)) for continuous variables were presented for each 
treatment group and overall. There were no tests of statistical significance nor confidence 
intervals (CIs) for differences between randomised groups on any baseline variable. 
Data collected at the 8-week, 3-, 6- and 9- months post injury follow-ups was summarised and 
the proportion of missing items from completed questionnaires examined. The patterns of data 
availability for primary and secondary outcomes from baseline to end of follow-up, were 
summarised for the two treatment groups as well as reasons for missingness where known. The 
nature and pattern of missing data (missing completely at random (MCAR); missing at random 
(MAR); or missing not at random (MNAR)) was explored. Differentiation was made between 
partially completed and fully missing outcome data. Validation rules for the primary outcome 
ATRS ensured that data was entered in the correct format, within valid ranges, minimising the 
chance of missing data. Where ATRS item responses were missing and at least half of the items 
were present, a pro-rata estimation of the ATRS score was imputed based on the average of the 
available ATRS item responses.  
Withdrawals and losses to follow-up were compared between the Functional Brace and Plaster 
Cast groups at each time-point and the reasons reported where known. Absolute risk 
differences (with 95% CIs) between the two groups were calculated, and the importance of 
differences identified using Chi-squared tests or Fisher’s exact test if appropriate. Where 
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participants were identified with tendon re-ruptures followed by surgery, the participant was 
not treated as loss to follow-up. Deaths and their causes were reported separately. 
Quality assurance and the compliance with treatment was assessed. Treatment received was 
reported by intervention group and summarised with reasons for not receiving the assigned 
treatment where this was possible.  
For all analyses tests were two sided and considered to provide evidence for a significant 
statistical difference if p-values to three decimal places were less than 0.05 (5% significance 
level) and any reported treatment estimates will be presented with their associated 95% CI.  
2.15.6 Analysis of primary outcome 
The primary outcome ATRS at nine months post injury was reported for each of the two 
treatment groups, Functional Brace and Plaster Cast. The main findings of the trial show the 
difference in the ATRS between the two treatment groups, estimated with a linear mixed effects 
regression model, including outcome information from all follow-up points and adjusting for 
recruitment centre, age, gender and baseline ATRS. An additional fully adjusted model 
included centre, age, gender, baseline ATRS, smoking status and diabetic condition as 
prognostic variables. Important clinician-specific effects were not expected as individual 
clinicians only treated a small number of patients, but recruitment centre was included in the 
model as a random effect factor to adjust for potential cluster differences. Estimates of 
treatment effects were presented with 95% CIs. Histograms and residual checks were used to 
assess an approximate normal distribution of the ATRS and where relevant the medians and 
IQRs reported for each treatment group.  
An unadjusted analysis was also undertaken to assess the differences between treatment groups 
using a Student t-test, based on a Normal approximation for the ATRS score. Estimates of 
treatment effects were presented with 95% CIs for both unadjusted and adjusted analyses. The 
ITT adjusted analysis of the primary outcome ATRS was used to determine the success or 
otherwise of the trial.  
Sensitivity analyses to examine the robustness of conclusions to different assumptions were 
conducted for the CACE population. Compliance was defined as using the allocated 
intervention for a minimum of six weeks and further sensitivity analysis was undertaken using 




Supplementary analysis  
In order to explore recovery in the two treatment groups over time, a further analysis of the 
ATRS was conducted. This summarised longitudinal data collected at all four time-points to a 
single value, the area under the curve (AUC) 39 in order to facilitate comparison of the ATRS 
between treatment groups over time. Parameter estimates from the mixed effects models were 
used to calculate AUCs for each treatment group from baseline to the 9-month post injury 
follow-up. This provided an overall estimate of recovery over time in each group. Larger ATRS 
scores were associated with fewer limitations/difficulties related to the injured Achilles tendon, 
therefore larger AUCs were suggestive of improved function. AUCs for each treatment group 
and their difference calculated using a t-test were presented together with their associated 95% 
CI. The lincom command in Stata was used to calculate AUC for each group. This analysis was 
also conducted for the EQ-5D utility score and the EQ-5D VAS. 
2.15.7 Analysis of secondary outcome 
Continuous secondary outcomes ATRS at 8 weeks, 3 and 6 months post injury follow-up and 
EQ-5D-5L were evaluated and analysed for the ITT population using the methodology 
described for the primary outcome. Histograms and residual checks were used to assess 
whether these variables were approximately normally distributed.  Means and SDs were 
reported at the 8-weeks, 3-, 6- and 9-month post-injury follow-up time-points and medians and 
IQRs where appropriate. A linear mixed effects regression model including outcome 
information from all time-points and adjusting for recruitment centre, age, gender and baseline 
pre-injury outcome values was used to examine the difference between the treatment groups.  
Complications in each of the treatment groups were reported as numbers (with percentages) 
and compared over the nine months study period using Chi-squared tests or Fisher’s exact test. 
The results were reported with their associated 95% CI and p-values for comparison between 
the two treatment groups. The population for this analysis was ITT. Complications were further 
grouped for to identify the number of patients with one or more complications at each time-
point. 
Sensitivity analyses were also conducted for the secondary outcome EQ-5D-5L analysis using 





2.16 Health economics methods  
2.16.1 Overview 
The main objective of the health economic evaluation was to assess the comparative cost-
effectiveness of the two non-surgical treatment options (plaster cast versus functional 
bracing) for patients with a primary (first-time) rupture of the Achilles tendon. To achieve 
this, a systematic comparison of the cost of resource inputs used by participants in the two 
arms of the trial and consequences associated with the interventions was conducted. The 
primary analysis adopted a NHS and PSS perspective, in accordance with National Institute 
for Health and Care Excellence (NICE) recommendations 40. A societal perspective for costs 
was adopted for the sensitivity analysis and this included private costs incurred by trial 
participants and their families, as well as productivity losses and loss of earnings as a result 
of work absences. 
 
The economic evaluation took the form of a cost–utility analysis, expressed in terms of 
incremental cost per QALY gained. The time horizon covered the period from randomisation 
to end of follow-up at 9 months post injury. Costs and outcomes were not discounted due to 
the short, 9-month, time horizon adopted for this within-trial evaluation. 
 
2.16.2 Measurement of resource use and costs  
 
Data were collected on:  
i) Resource use and costs associated with delivery of the interventions (direct 
intervention costs)  
ii) Broader health and social care service use during the 9 months of follow-up  
iii) Broader societal resource use and costs – this encompassed private medical costs 
and lost productivity costs such as lost income over the 9 months of follow-up. 
All costs were expressed in pounds sterling and valued in 2017-18 prices. When appropriate, 
costs were inflated or deflated to 2017–18 prices using the Hospital and Community Health 




Direct intervention costs 
Direct intervention costs comprised costs associated with the application of the two 
interventions. This included cost of the walking boot and wedges, materials used for plaster 
cast, the cost associated with fitting the interventions to patients (hospital staff time), and the 
costs associated with any changes required to either plaster cast or functional bracing (Table 
2). Information on how long it takes to deliver each intervention and type and volume of 
materials used was collected at each recruitment centre, through a questionnaire completed 
by recruitment centre staff in consultation with staff responsible for fitting the functional 
brace or applying the plaster cast.  Unit costs for staff were obtained from the Personal Social 
Services Research Unit (PSSRU) Unit Costs of Health and Social Care 2018 compendium 42 
and were multiplied by the median time it takes to deliver each intervention. The median time 
for fitting a functional brace was 10, 11 and 17.5 minutes for a plaster technician, nurse and 
other staff (included physiotherapists, orthotists and occupational therapists) respectively. 
The median time to change wedges was 5 minutes for a plaster technician and nurse and 10 
minutes for ‘other’ staff. The median time for changing a plaster cast was 15 minutes for a 
plaster technician and 17.5 minutes for a nurse. The base case analysis assumed costs of a 
plaster technician. Unit costs of plaster cast materials, walking boots and wedges were 
obtained from the 2018 NHS Supply chain catalogue. The total direct intervention cost for 




Table 2: Unit costs associated with direct intervention costs for plaster cast and functional bracing 
Resource item  Unit cost Unit of 
analysis  
Source of unit 
cost 
Direct intervention costs    
Functional brace:    
Walking boot1 cost by brand:    
Samson walking boot 
Donjoy walking boot 














Plaster cast:    
Plaster cast materials 2    
2 x 7.5cm poly rolls 
2x 10 cm poly rolls 
£2.83 
£6.69 
Per roll NHS Supply 
Chain Catalogue 
2018 
Fibreglass casting tape 5 inch x3.6m £11.48 Per roll NHS Supply 
Chain Catalogue 
2018 
1m stockinette £3.23 Per roll NHS Supply 
Chain Catalogue 
2018 
2 x rolls of 5inch wool bandage  £3.00 Per roll NHS Supply 
Chain Catalogue 
2018 
1 Unit costs for all other walking boot brands that patients received (not pre-specified in case report forms) were 
individually-derived from the NHS Supply Chain Catalogue. 
2 Unit costs for any other plaster cast materials that sites use (not pre-specified in site-specific questionnaire) 
were individually-derived from the NHS Supply Chain Catalogue 2018. 
 
 
2.16.3 Measuring broader resource use 
Broader resource use data were collected using follow-up questionnaires completed by trial 
participants at the four follow-up assessment points: 8 weeks, 3 months, 6 months and 9 
months post injury.  The questionnaires captured details of inpatient and day case admissions, 
outpatient and emergency care attendances, encounters with primary or community health 
and social care services, medication use and walking aids provided/self-purchased, as well 
adaptations to home environments. In addition, the questionnaires captured the direct non-
medical costs (including travel expenses) incurred by patients and their carers, as well as 
number of days off work and gross loss of earnings attributable to the trial participant’s 




2.16.4 Valuation of resource use 
Resource inputs were valued by attaching unit costs derived from national compendia in 
accordance with NICE’s Guide to the Methods of Technology Appraisal 2013 40. The key 
databases for deriving unit cost data included the Department of Health and Social Care’s 
Reference Costs 2016–17 schedules 43, the PSSRU’s Unit Costs of Health and Social Care 
2018 compendium 42, the 2018 NHS Prescription Cost Analysis database for England 44, 2018 
volumes of the British National Formulary 45, and the NHS Supply Chain Catalogue 2018 46. 
Table 27 (Appendix 4) gives a summary of the unit costs values and data sources for broader 
resource use categories identified within the follow-up questionnaires.  
 
Per diem costs for hospital inpatient admissions during the follow-up period were calculated 
individually as a weighted average of Healthcare Resource Group (HRG) codes of related 
procedures and/or clinical diagnoses. For example, the average cost per day for an inpatient 
stay in a medical ward to treat a PE was calculated as the sum total of weighted average HRG 
codes (DZ09J – DZ09Q; PE with or without interventions) divided by average length of stay 
across elective and non-elective inpatient services. The individual HRG codes were derived 
using the NHS HRG4 2017/18 Reference Cost Grouper software version RC1718 (NHS 
Digital, Leeds, UK). The Department of Health and Social Care’s Reference Costs 2017–18 
43 schedule was used to assign the costs for each of the derived HRG codes.  
 
Costs for community-based health and social care services were calculated by applying unit 
costs extracted from national tariffs, primarily extracted from the PSSRU Unit Costs of 
Health and Social Care 2018 compendium 42, to resource volumes. Costs of medications for 
individual participants were estimated based on their reported doses and frequencies, when 
these were available, or based on an assumed daily doses using British National Formulary  45 
recommendations. When a dose range was reported as ‘as required’ or when the quantities 
were not recorded, we assumed a mean cost for that medication item based on the 
prescription cost analysis values (net ingredient cost per item). In cases where medication 
dosages were missing, we conservatively assumed that the patient received the same dosage 




The costs of walking aids and adaptations (equipment participants receive to manage their 
injury and make daily lives easier) were derived by combining data on number and type of 
items received with their unit cost values. Unit cost values were derived from the NHS supply 
chain catalogue 46 if equipment was provided by a health provider during the trial follow-up 
period. Where aids and adaptations were self-financed, the costs were provided by 
participants themselves.  
 
We used data on sex and employment status-specific median earnings from the UK national 
annual survey of hours and earnings 47 to derive the costs of time taken off work. The 
employment status of trial participants was derived from self-reported work status 
information. Broader societal costs were calculated by combining the productivity losses and 
income losses attributable to work absences. 
 
Summary statistics were generated for resource use variables by treatment allocation and 
assessment point. Between treatment-group differences in resource use and costs at each 
assessment point were compared using the two sample t-test. Statistical significance was 
assessed at the 5% significance level. Standard errors are reported for treatment group means 
and bootstrap 95% confidence intervals for the between-group differences in mean resource 
use and cost estimates. 
 
2.16.5 Measurement of outcomes  
In accordance with NICE guidelines, the primary health outcome for the health economic 
evaluation was the QALY metric. 48 QALYs are a measure that combines quantity and 
preference-based health-related quality of life (HRQoL) into a single metric. To calculate 
QALYs, it is imperative to obtain health state values for participants within the trial. Health-
related quality of life of trial participants was assessed at baseline (both pre and post injury), 
and 8 weeks, 3 months, 6 months and 9 months post injury using the EuroQoL EQ-5D-5L 
instrument. 49 The EQ-5D-5L instrument defines health-related quality of life in terms of five 
dimensions: (1) mobility, (2) self-care, (3) usual activities, (4) pain/discomfort and (5) 
anxiety/depression. Responses in each dimension are divided into five ordinal levels coded: 
(1) no problems, (2) slight problems, (3) moderate problems, (4) severe problems, and (5) 
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extreme problems. Responses to each health dimension were categorised as optimal or sub-
optimal with respect to function where optimal level of function indicates no impairment (for 
example “no problems in walking about” for the mobility dimension) and sub-optimal 
function refers to any functional (below level 1) impairment. Between-group differences in 
optimal versus sub-optimal level of function for each health dimension were compared at 
each time-point using chi-squared (χ2) tests.  
 
Responses to the EQ-5D-5L instrument were converted into health utility scores using the 
EQ-5D-5L Crosswalk Index Value Calculator currently recommended by NICE, 50 which 
maps the EQ-5D-5L descriptive system data onto the EQ-5D-3L valuation set.  Detailed 
description on the mapping methodology is described elsewhere. 50 QALYs were generated 
for each patient using the area under the baseline-adjusted utility curve, assuming linear 
interpolation between health utility measurements across assessment points.  
 
Health utility values and QALYs accrued over the 9-month follow-up period were 
summarised by treatment group and assessment point and presented as means and associated 
standard errors; between group differences were compared using the two-sample t-test, 
similar to the descriptive analyses of resource inputs and costs. 
2.16.6 Cost-effectiveness analysis methods  
Missing data 
Missing data are a common occurrence within randomised controlled trials: participants may 
be lost to follow-up, questionnaires unreturned or responses to individual questionnaire items 
may be missing. 51 Because costs and outcomes of individuals with missing data may differ 
systematically to those with fully observed data, it is important to handle missing data using a 
principled approach that is justified by, amongst other factors, the missing data mechanism.  
Missing costs and health utility data were imputed at each time-point using fully conditional 
multiple imputation by chain equations, implemented through the MICE package, under the 
missing at random (MAR) assumption. Appropriateness of the MAR assumption was 
assessed by: (i) investigating the missing data patterns (monotonic vs. non-monotonic), and 
(ii) comparing attributes of participants with and without missing costs and health-related 




The multiple imputation model used baseline covariates (age, gender), costs and health utility 
values at each follow-up time-point to impute unobserved costs and health utility values, such 
that, for example, missing costs at 9 months were imputed using data on baseline covariates, 
costs at 8 week, 3 months and 6 months and health utility values at each follow-up time-
point. The imputations were implemented separately by treatment allocation in line with best 
practice. 52 The imputation was run 50 times, following the rule of thumb that the number of 
imputations should be at least greater than the proportion of missing data. 52 
 
Bivariate regressions using a seemingly unrelated regression model (Sureg) were used to 
independently analyse the multiply imputed datasets so as to estimate the costs and QALYs 
in each treatment group over the 9-month trial horizon. Joint distributions of costs and 
outcomes from the original data set were generated through non-parametric bootstrapping 
and changes in costs and QALYs were calculated for each sample. A total of 1000 bootstrap 
samples were drawn and means for both incremental costs and incremental QALYs (with 
associated 95% CIs) were calculated. Estimates from each imputed dataset were combined 
using Rubin’s rule 53 to generate overall mean estimates of costs and QALYs and their 
standard errors (SE). The latter reflects the variability within and across imputations. The 
imputation model was validated by assessing the distributions of imputed and observed 
values. A mixed model with adjustment for baseline pre-injury EQ-5D health utility scores is 
also presented for comparison.   
 
Presentation of cost-effectiveness results 
Cost-effectiveness results are expressed in terms of the incremental cost-effectiveness ratio 
(ICER) and calculated as the difference between treatments in mean total costs divided by 
mean total QALYs. Given the pattern of results, plaster cast has been selected as the referent 
and functional brace as the comparator, i.e. functional brace minus plaster cast, for the 
estimation of ICER values. The bootstrap replicates generated by the non-parametric 
bootstrapping, described in the sub-section ‘Missing data’, were used to populate cost-
effectiveness scatterplots. Cost-effectiveness acceptability curves, which showed the 
probability that functional brace is cost-effective relative to plaster cast across a range of 
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cost-effectiveness thresholds, were also generated based on the proportion of bootstrap 
replicates with positive incremental net benefits. The net monetary benefit (NMB) of using 
functional brace versus plaster cast was also calculated across three pre-specified cost-
effectiveness thresholds, namely £15,000 per QALY , 54 £20,000 per QALY and £30,000 per 
QALY. 55 A positive incremental NMB indicates that the functional brace is cost-effective 
compared with the plaster cast at the given cost-effectiveness threshold. For the purpose of 
the secondary analysis that adopted the ATRS as the health outcome measure of interest, the 
NMB was estimated at cost-effectiveness thresholds of £100 - £500 per unit change in ATRS 
score. We failed to identify any external evidence on economic values for changes in ATRS 
score and therefore a range of arbitrary threshold values had to be selected for this analysis.  
 
Sensitivity and secondary outcomes analyses 
Several sensitivity analyses were conducted to test the robustness of the cost-effectiveness 
estimates. These involved re-estimating the main cost-effectiveness outcomes under the 
following scenarios: (1) restricting the analyses to complete cases (i.e. those with complete 
cost and outcome data over the 9-month follow-up period); (2) adopting a wider societal 
perspective that included private costs incurred by trial participants and their families, as well 
as economic losses placed on attributable work absences; and (3) Estimating incremental 
cost-effectiveness using a CACE population.  In addition, as a secondary analysis, cost-
effectiveness was estimated using the ATRS, rather than the QALY, as the health outcome 
measure of interest.  
 
Longer-term economic modelling 
The study protocol also allowed for decision-analytic modelling to estimate longer-term cost-
effectiveness of functional bracing or plaster cast provided the costs and health outcomes did 
not converge at the end of the 9-month post injury follow-up period. 
 
2.17 Data management 
According to the standard operating procedures of the OCTRU, data management procedures 
were defined in a Data Management Plan. This covered trial databases and data handling, 
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definition of critical data fields, forms and questionnaires used, data collection, how protocol 
deviations were recorded, data rulings, handling data deviations, data security and 
confidentiality, dataset closure, archiving and data sharing. Each Data Management Plan 
version was signed off by the Chief Investigator and Trial Statistician.  
The Monitoring Plan determined the need for central and on-site data monitoring. All 
recruitment centres were monitored centrally. The monitoring plan specified that on-site 
monitoring was not required for this trial and no monitoring visits were conducted. 
Statistics on data collection, data entry and query management were presented to each TMG 
meeting for oversight. 
UK legislation requires data to be anonymised as soon as it is practical to do so. Participants 
were identified only by initials and a participant number on UKSTAR questionnaires and in 
the study database. All documents were stored securely and only accessible by study staff and 
authorised personnel. Personal data and sensitive information required for the study were 
collected directly from trial participants and hospital notes. All personal information received 
in paper format for the trial was held securely and treated as strictly confidential. Personal 
data was stored separately from study outcomes, in lockable cabinets in secure keycard 
accessed rooms in the Kadoorie Centre in the John Radcliffe Hospital and in the Botnar 
Research Centre, University of Oxford, in Oxford. All paper and electronic data will be 
retained for at least five years after completion of the trial. 
2.18 Patient and public involvement 
The UKSTAR TSC and TMG both included a patient representative as a PPI member. Mrs S 
Webb was TSC PPI representative and attended meetings from the initial meeting and Mr R 
Grant was PPI representative at TMG meetings from September 2017.  
2.19 Ethical approval and monitoring 
2.19.1 Ethical approval 
The study was given a favourable opinion by the South Central - Oxford B Research Ethics 
Committee on 07 April 2016 (Research Ethics Committee reference 16/SC/0109) and each 
recruitment centre was granted site-specific approval from its NHS Trust Research and 
Development department before trial commencement.  
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2.19.2 Data and Safety Monitoring Committee 
The DSMC was a group of independent experts external to the trial who assessed the 
progress, conduct, participant safety and critical endpoints of the trial. The UKSTAR DSMC 
adopted a DAMOCLES charter 56 which defined its terms of reference and operation in 
relation to oversight of the trial. They reviewed copies of data accrued to date including 
information on allocation balance, data quality and participant safety summarised by 
treatment group, and assessed the screening algorithm against the eligibility criteria. No 
formal interim analysis of the outcome data was requested for review by the DSMC. During 
the period of recruitment to the trial, all information supplied to the DSMC members was 
done in strict confidence. They also considered emerging evidence from other related trials or 
research and reviewed related SAEs that have been reported. They were able to advise the 
chair of the TSC at any time if, in their view, the trial should be stopped for ethical reasons, 
including concerns about participant safety. DSMC meetings were held at least annually 
during the recruitment phase of the study. 
2.19.3 Trial Steering Committee 
The TSC, which included independent members, and had an independent Chair, provided 
overall supervision of the trial on behalf of the funder. Its terms of reference were defined in 
a TSC Charter, agreed with The Health Technology Assessment (HTA) Programme, who 
also approved the appointment of TSC members. The TSC’s remit was to: 
 monitor and supervise the progress of the trial towards its interim and overall 
objectives; 
 review at regular intervals relevant information from other sources; 
 consider the recommendations of the DSMC; 
 inform the funding body of the progress of the trial. 
TSC meetings were held at least annually during the recruitment phase of the study. 
2.19.4 Trial Management Group 
The TMG was made up of the Study Investigators and staff working on the project. This 
group oversaw the day-to-day running of the trial and met regularly throughout the lifetime of 
the study. 
2.20 Summary of changes to the trial protocol 
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All protocol versions can be found on the NIHR journals library website at [URL to be 
provided].  
The changes to the project protocol are summarised in Table 3.   
 




Date  Details of Changes made 
1 27 January 2016 The first version. 
2 18 August 2016 References to fax removed; replaced with description of sending 
confidential documents to a secure nhs.net email. 
Addition of resource use questionnaire at eight weeks 
Clarification of data collection roles of recruitment centre staff and 
UKSTAR office staff. 
Update to the statistical analysis section of the protocol so that it 
reflects the statistical analysis plan for the trial. 
Clarification regarding the consent process. 
Correction of typographical errors and clarifications. 
3 10 July 2017 Clarification that questionnaires at the 3, 6 or 9 month time-points 
may be sent electronically to patients via email or text, as an 
alternative to by post. 
4 19 September 2017 
(not issued) 
Update of sample size to a maximum of 550 patients. 
5 23 October 2017 Correction of protocol version number from 4.1 to 5.0. 
6 16 May 2018 Addition of Study Within a Trial to assess the effect of thank you 
emails on follow-up rates. 
Updates to Study personnel, Trial Steering Committee 
membership and sponsor address details. 
Correction of minor typographical errors. 
7 13 November 2018 Removal of Study Within a Trial. 
Addition of thank you letter to participants after final follow-up. 
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3. Clinical trial results 
3.1 Study participants 
Patients with an Achilles tendon rupture typically attend the Emergency Department at their 
local hospital and, following their diagnosis, are referred to the next available fracture/trauma 
clinic to discuss the management of their injury. 
The flow of participants through the study is summarised in 
 
Figure 16: EQ-5D Self Care from baseline pre-injury to 9 months. EQ-5D Self Care values 





Figure 17: EQ-5D Usual Activities from baseline pre-injury to 9 months. EQ-5D Usual 
Activities values range from 1 to 5 with 1 indicating no problems 
 
 
Figure 18: EQ-5D Pain Discomfort from baseline pre-injury to 9 months. EQ-5D Pain 






Figure 19: EQ-5D Anxiety Depression from baseline pre-injury to 9 months. EQ-5D Anxiety 
Depression values range from 1 to 5 with 1 indicating no problems 
. This includes details on the total number of patients referred to the trauma clinic with an 
Achilles tendon rupture and those randomised. The availability of the primary outcome for 
analysis is also reported by intervention group as well as the total number excluded from the 




One thousand and seventy-six eligible participants were screened from July 2016 to May 2018 
from 39 NHS hospitals in across England and Wales (
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Figure 17: EQ-5D Usual Activities from baseline pre-injury to 9 months. EQ-5D Usual 
Activities values range from 1 to 5 with 1 indicating no problems 
 
 
Figure 18: EQ-5D Pain Discomfort from baseline pre-injury to 9 months. EQ-5D Pain 






Figure 19: EQ-5D Anxiety Depression from baseline pre-injury to 9 months. EQ-5D Anxiety 
Depression values range from 1 to 5 with 1 indicating no problems 
). Of these, five hundred and forty participants consented to taking part in the trial. Reasons 
why patients were not included in the trial are presented. Participants attended clinic visits at 
the time of randomisation (baseline) and at the 8-week follow-up. Participants were 
additionally contacted by the trial team via post, email or telephone to complete follow-up 
questionnaires at 3, 6 and 9 month post injury. Two participants were randomised in error 
before consenting and are therefore not included in the numbers allocated to each treatment 
group.  
3.3 Baseline characteristics 
The randomisation was stratified by centre and the allocation of participants to the intervention 
groups in each centre and the overall numbers is given in Table 4. The descriptive 
characteristics of the participants included in the ITT population are summarised by 
intervention group and overall in Table 5. These values are presented as numbers and 
percentages for categorical factors and means and SD or medians and IQR as appropriate for 
continuous variables. These variables all appear well balanced across the two treatment groups. 
The distribution of participant ages by gender at enrolment is shown in Error! Reference 
source not found. This distribution has a peak in male patients aged 30-40 years and in female 
patients aged 40-60 years. Baseline values of Patient Reported Outcomes Measures (PROMs); 
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ATRS and EQ-5D-5L) are summarised by intervention group in Table 6. ATRS, values range 
from 0 to 100 with lower scores indicating more functional limitations; EQ-5D utility scores 
range from -0.511  to 1 with higher scores indicating better quality of life, 0 is equivalent to 
death; EQ-5D VAS scores range from 0 to 100 with higher scores indicating better quality of 






Treatment received:  
 Plaster cast (n= 247) 
 Functional brace (n= 17); Reasons: 
- patient decision (n= 13); 
- clinician decision (n=3);  
- incorrect diagnosis (n=1) 
 Unknown (n=1) 
Completed baseline (n=264) 
 
Patients referred to the trauma / orthopaedic clinic 
with Achilles tendon rupture (n= 1451) 
Patients not meeting eligibility criteria (n= 375)  
 < 16 years old (n= 3) 
 Had previous Achilles tendon rupture (n= 37) 
 Having surgery (n= 120) 
 Presented to the treating hospital > 14 days 
after injury (n= 155) 
 Unable to adhere to trial procedures or 
complete questionnaire (n= 46) 
 Other (n= 14)* 
Randomised (n= 542) 
Treatment received: 
 Functional brace (n= 269) 
 Plaster cast (n= 4); Reasons: 
- patient decision (n=1) 
- clinician decision (n=1) 
- medical resources unavailable (n=2) 
 
Completed baseline (n=273) 
Included in primary analysis (n=257); 
Excluded from primary analysis (n=9);  
Reasons:  -   withdrew (n=6) 
- missing data (n=3 ) 
 
Included in primary analysis (n=270); 
Excluded from primary analysis (n= 4);  
Reasons: - withdrew (n=2) 
- death (n=1) 
- missing data (1) 
 
Allocated to Plaster cast  
(n= 266) 
 
Allocated to Functional brace  
(n= 274) 
Patients eligible but not randomised (n= 534)  
 No staff available to register 
patient/patient missed in error (n = 97) 
 Clinician’s choice (n= 50) 
 Walking boot or plaster cast supplies 
unavailable (n= 2) 
 Patient declined (n= 385) 
Eligible patients (n= 
1076) 
Withdrew (n= 1) Withdrew (n= 1) 
Figure 1: UKSTAR Consort Flow Diagram 
 Not consented (n= 2) 
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Table 4: Stratification factor (recruitment centre) according to intervention group and overall  
 Plaster Cast Functional Brace Overall 
 (n = 266) (n = 274) (n = 540) 
 n % n % n % 
Trial centre a       
          ABD 31 11.7% 33 12.0% 64 11.9% 
          AIR 11  4.1% 12  4.4% 23  4.3% 
          BRT 4  1.5% 4  1.5% 8  1.5% 
          CHX 1  0.4% 1  0.4% 2  0.4% 
          CUH 12  4.5% 14  5.1% 26  4.8% 
          DBH 7  2.6% 6  2.2% 13  2.4% 
          DUN 9  3.4% 10  3.6% 19  3.5% 
          ENH 17  6.4% 18  6.6% 35  6.5% 
          GEH 11  4.1% 12  4.4% 23  4.3% 
          GLA 3  1.1% 5  1.8% 8  1.5% 
          HCH 2  0.8% 3  1.1% 5  0.9% 
          HEY 3  1.1% 2  0.7% 5  0.9% 
          INV 6  2.3% 5  1.8% 11  2.0% 
          KCH 1  0.4% 0  0.0% 1  0.2% 
          LDH 4  1.5% 4  1.5% 8  1.5% 
          LDS 13  4.9% 14  5.1% 27  5.0% 
          MKN 12  4.5% 12  4.4% 24  4.4% 
          MPH 6  2.3% 6  2.2% 12  2.2% 
          MTW 6  2.3% 7  2.6% 13  2.4% 
          MYH 2  0.8% 1  0.4% 3  0.6% 
          NLG 5  1.9% 6  2.2% 11  2.0% 
          NTE 1  0.4% 3  1.1% 4  0.7% 
          NUH 9  3.4% 8  2.9% 17  3.1% 
          OUH 3  1.1% 3  1.1% 6  1.1% 
          PLY 10  3.8% 9  3.3% 19  3.5% 
          QEH 13  4.9% 12  4.4% 25  4.6% 
          RBK 4  1.5% 3  1.1% 7  1.3% 
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          RCH 6  2.3% 6  2.2% 12  2.2% 
          RED 5  1.9% 5  1.8% 10  1.9% 
          RTH 5  1.9% 5  1.8% 10  1.9% 
          SAL 6  2.3% 7  2.6% 13  2.4% 
          SHC 5  1.9% 4  1.5% 9  1.7% 
          SLF 8  3.0% 7  2.6% 15  2.8% 
          UHS 6  2.3% 6  2.2% 12  2.2% 
          ULH 11  4.1% 10  3.6% 21  3.9% 
          WAR 1  0.4% 3  1.1% 4  0.7% 
          WHI 6  2.3% 6  2.2% 12  2.2% 
          WYT 1  0.4% 2  0.7% 3  0.6% 
a See Appendix 2 for full NHS Trust Hospital name  
 
Table 5: Descriptive characteristics of ITT population by treatment group at baseline. Values 
are n (%) for categorical variables, and mean (SD) or median (IQR) for continuous outcomes. 
 Plaster Cast Functional 
Brace 
Overall 
 (n = 264) (n = 274) (n = 538) 
Gender, N (%)    
      Male 213 (80.7%) 213 (77.7%) 426 (79.2%) 
      Female 51 (19.3%) 61 (22.3%) 112 (20.8%) 
Age, mean (SD) 49.0 (13.9) 48.3 (13.8) 48.7 (13.8) 
BMI, kg/m2, mean (SD), N 27.5 (4.5), 255 27.8 (5), 265 27.7 (4.8), 520 
Days since injury, median (IQR)  5.0 (2.5, 8)  5.0 (2, 8)  5.0 (2, 8) 
Mechanism of injury, N (%)    
      Fall from height 3 (1.2%) 8 (3%) 11 (2%) 
      Fall on steps/stairs 22 (8.4%) 14 (5.1%) 36 (6.7%) 
      Fall/trip from standing height 6 (2.4%) 11 (3.9%) 17 (3.2%) 
      Sports 187 (70.8%) 192 (70.2%) 379 (70.4%) 
      Walking 14 (5.4%) 28 (10.2%) 42 (7.8%) 
      Other 14 (5.4%) 6 (2.1%) 20 (3.7%) 
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Side of injury, N (%)    
      Right 122 (46.2%) 138 (50.4%) 260 (48.3%) 
      Left 142 (53.7%) 136 (49.5%) 278 (51.7%) 
Regular smoker, N (%)    
      No 225 (85.2%) 234 (85.5%) 459 (85.2%) 
      Yes 39 (14.7%) 39 (14.1%) 78 (14.4%) 
      Missing 0 (0%) 1 (0.3%) 1 (0.2%) 
Cigarettes (per day), median (IQR), N 10.0 (5, 15), 39 10.0 (5, 15), 39 10.0 (5, 15), 78 
Smoking duration (years), median (IQR), N 20.0 (10, 25), 38 20.5 (13, 30), 38 20.0 (10, 30), 76 
Alcohol units (per week), N (%)    
      0-7 units 162 (61.5%) 161 (58.8%) 323 (60%) 
      8-14 units 49 (18.6%) 65 (23.7%) 114 (21.3%) 
      15-21 units 40 (15.3%) 35 (12.9%) 75 (13.8%) 
      >21 units 12 (4.5%) 10 (3.6%) 22 (4.2%) 
      Missing 1 (0.3%) 3 (1.2%) 4 (0.6%) 
Taking the following medication, N (%)    
        Fluoroquinolone Antibiotics 5 (1.9%) 4 (1.5%) 9 (1.7%) 
        Steroids 7 (2.7%) 14 (5.1%) 21 (3.9%) 
        DMARDs 2 (0.8%) 1 (0.4%) 3 (0.6%) 
        Diabetic Medication 5 (1.9%) 14 (5.1%) 19 (3.5%) 
        Regular Analgesia 23 (8.7%) 14 (5.1%) 37 (6.9%) 
        Anticoagulant Medication 66 (25%) 78 (28.5%) 144 (26.8%) 
Diagnosis prior to injury, N (%)    
        Diabetes 5 (1.9%) 18 (6.6%) 23 (4.3%) 
        Rheumatoid Arthritis 0 (0%) 3 (1.1%) 3 (0.6%) 
        Lower Limb Fracture (last 12 months) 1 (0.4%) 4 (1.5%) 5 (0.9%) 
        Ligament, tendon or nerve injury to lower 
limb (last 12 months) 
5 (1.9%) 8 (2.9%) 13 (2.4%) 
        Arthritis 21 (8%) 21 (7.7%) 42 (7.8%) 
        Achilles tendinopathy 10 (3.8%) 10 (3.6%) 20 (3.7%) 
Employment status    
      Full-time employed 160 (60.6%) 168 (61.3%) 328 (61%) 
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      Part-time employed 18 (6.8%) 15 (5.5%) 33 (6.1%) 
      Self-employed 39 (14.8%) 29 (10.6%) 68 (12.6%) 
      Retired/looking after home/inactive 35 (13.3%) 41 (15%) 76 (14.1%) 
      Unpaid work 1 (0.4%) 2 (0.7%) 3 (0.6%) 
      Unemployed 8 (3%) 8 (2.9%) 16 (3%) 
      Full time student 3 (1.1%) 9 (3.3%) 12 (2.2%) 
      Missing  0.0 (0%) 2.0 (0.7%)  2.0 (0.4%) 
Employment category    
      Unskilled manual 11 (4.2%) 11 (4%) 22 (4.1%) 
      Skilled manual 62 (23.5%) 64 (23.4%) 126 (23.4%) 
      Unskilled non-manual 6 (2.3%) 7 (2.6%) 13 (2.4%) 
      Skilled non-manual 29 (11%) 21 (7.7%) 50 (9.3%) 
      Professional 109 (41.3%) 108 (39.4%) 217 (40.3%) 
      Missing  0.0 (0%)  3.0 (1%)  3.0 (0.6%) 




Figure 2: Participant age (years) at randomisation by gender 
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Table 6: PROMs by intervention group for ITT population at baseline. Values are median 
(IQR) unless otherwise specified. 
PROM: patient reported outcome measure; IQR: inter-quartile range; ATRS = Achilles Tendon Rupture Score; 
VAS: Visual Analogue Scale ; SD: standard deviation 
 
3.4 Compliance 
Participants were considered compliant if they wore their allocated treatment following 
randomisation for a period of 6 weeks or more without any cross-over at baseline or treatment 






(n = 264) 
Functional Brace 
(n = 274) 
Overall 
(n = 538) 
ATRS pre injury 100 (96.5, 100), 264 100 (94, 100), 273 100 (96, 100), 537 
EQ-5D VAS pre injury 90 (80, 95), 263 90 (80, 95), 273 90 (80, 95), 536 
EQ-5D VAS post injury, 
mean (SD), N 
57.6 (21.1), 262 58.3 (21.5), 273 58.0 (21.3), 535 
EQ-5D Utility pre injury 1 (1, 1), 262 1 (1, 1), 273 1 (1, 1), 535 
EQ-5D Utility post injury, 
mean (SD), N 




Table 7). The population compliant with treatment for 6 weeks or more was made up of 477 
(88.2%) participants overall, 212 (79.7%) of whom were in the Plaster Cast group and 265 
(96.7%) of whom were in the Functional Brace group. The number of patients compliant with 













Table 7:  Number of patients compliant to treatment 
 Plaster Cast  
(n = 266) 
Functional Brace  
(n = 274) 
 n % n % 
Compliance with treatment a      
                6 weeks or more 212 79.7% 265 96.7% 
                4 weeks or more 223 83.8% 268 97.8% 
                2 weeks or more 240 90.2% 268 97.8% 
a Compliance starts at randomisation. Each time point includes the period following the time point specified. 
 
Details of the treatment intervention received following randomisation are listed in Table 8. 
There were 247 (92.9%) participants in the Plaster Cast group and 269 (98.2%) who received 
their allocated treatment immediately at baseline. Those who did not receive the allocated 
treatment at baseline, received the opposite treatment instead or withdrew. A further 35 
participants (13.2%) in the Plaster Cast and 4 (1.5%) in the Functional Brace group changed 
from the treatment they were randomised to within the first six weeks and received the opposite 
treatment or surgery instead. The reasons why participants changed from their allocated 
treatment are listed in Table 9 and include patient decision, clinician decision, medical 
resources unavailable, incorrect Achilles tendon rupture diagnosis, surgery or withdrawal.  
 
Table 8: Details of the intervention received by treatment group 
 Plaster Cast 
 (n = 266) 
Functional Brace 
 (n = 274) 
 n % n % 
Received allocated treatment at baseline 247 92.9% 269 98.2% 
Changed treatment at baseline 19  7.1% 5  1.8% 
              Received opposite treatment 17  6.4% 4  1.5% 
              Withdrew 1  0.4% 1  0.4% 
              Unknown 1  0.4% 0  0.0% 
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Changed treatment within 6 weeks 
excluding changes at baseline 
35 13.2% 4  1.5% 
             Received opposite treatment 30 11.3% 1  0.4% 




Table 9: Reasons for changing allocated treatment in each intervention group 
 Plaster Cast 
(n = 54) 
Functional Brace 
(n = 9) 
 n % n % 
Reason for treatment change at baseline     
      Patient requested 13 24.1% 1 11.1% 
      Clinician decision 3  5.6% 1 11.1% 
      Medical resource unavailable 0  0.0% 2 22.2% 
      Incorrect Achilles tendon rupture 
diagnosis 
1  1.9% 0  0.0% 
      Withdrew 1  1.9% 1 11.1% 
      Unknown 1  1.9% 0  0.0% 
Reason for treatment change within 6 
weeks after baseline 
    
     Patient requested 18 33.3% 1 11.1% 
     Clinician decision 12 22.2% 0  0.0% 
     Surgery 5  9.3% 3 33.3% 
 
Details of the treatment received in each treatment group including time-point when the patient 
was allowed to fully bear weight, time-point when cast/brace was removed, number of cast 
changes, type of brace used, number of heel wedges and venous thromboembolism (VTE) 
prophylaxis are listed in Table 10. Data collected shows that the number of participants allowed 
to bear weight early was higher in the Functional Brace than in the Plaster Cast group. 




patients who did not change from their allocated treatment in the first six weeks following 
randomisation. 
There were no differences between the two treatment groups in the time-point when the plaster 
cast/functional brace was removed.  On average, patients in the Plaster Cast group changed 
their plaster cast three times throughout the treatment period. The most frequently used 
functional brace make was Aircast (44.5%) and the median number of heel wedges was 3, 
although this varied from zero to five, depending on time-point. VTE prophylaxis was offered 
to more patients in the Plaster Cast group (187, 70.3%) than in the Functional Brace group 
(158, 57.7%). The type of VTE treatment used was Low Molecular Weight Heparin (LMWH) 
and oral anticoagulant in similar proportions across the two groups.  
 
Table 10. Details of treatment received for each treatment group 
 Plaster Cast (n = 266) Functional Brace (n = 274) 
 n % n % 
Time point when patient is allowed to fully 
bear weighta  
    
              Baseline 6  2.8% 121 45.7% 
              2 weeks 7  3.3% 24  9.1% 
              4 weeks 15  7.1% 26  9.8% 
              6 weeks 99 46.7% 30 11.3% 
              8 weeks or more 81 38.2% 57 21.5% 
              Unknown 0  0.0% 1  0.4% 
              Missing 4  1.9% 6  2.3% 
Time point when brace/cast is removed     
             Before 2 weeks 1  0.4% 1  0.4% 
             2 weeks 1  0.4% 2  0.7% 
             4 weeks 4  1.5% 1  0.4% 
             6 weeks 25  9.4% 10  3.6% 
             8 weeks 164 61.7% 167 60.9% 
             Still not removed 12  4.5% 76 27.7% 
Number of plaster cast changes over 8 weeksb  3.0  (1, 6), 241  N/A N/A 
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Functional brace make at baseline     
             Donjoy N/A N/A 15  5.5% 
             Samson N/A N/A 10  3.6% 
             Aircast N/A N/A 122 44.5% 
             Ossur N/A N/A 64 23.4% 
             VACOped N/A N/A 25  9.1% 
             Promedics N/A N/A 23  8.4% 
             Not known N/A N/A 5  1.8% 
Number of heel wedges in functional brace   Median Range, N 
             Baseline N/A N/A  3.0  (0, 5), 263  
             2 weeks N/A N/A  3.0  (0, 4), 258  
             4 weeks N/A N/A  2.0  (0, 4), 258  
             6 weeks N/A N/A  1.0  (0, 4), 260  
             8 weeks N/A N/A  0.0  (0, 4), 258  
VTE prophylaxis 187 70.3% 158 57.7% 
VTE treatment     
             Low Molecular Weight Heparin  148 79.1% 120 75.9% 
             Oral Anticoagulant 39 20.9% 38 24.1% 
VTE treatment duration (weeks)b  8.0  (0, 12), 181   8.0  (1, 12), 156  
a Not included are patients who changed their treatment in the first 6 weeks 
b Median (Range), N 
VTE: venous thromboembolism 
 
3.5 Numbers analysed 
The ITT population included all patients who were randomised and gave consent to participate 
in the trial. These patients were analysed in the groups they were allocated to and was used in 
the analysis of PROMs. Data for the two randomised participants who did not give their consent 
was excluded from the analysis. This population was made up of 540 participants overall, 266 
of whom were in the Plaster Cast group and 274 of whom were in the Functional Brace group. 
Analyses of all primary and secondary outcomes were performed for this population. 
The CACE population  37 included all randomised participants compliant with treatment for 6 





Table 11 provides details on the available data at each follow-up time-point, including the 
number of CRFs and PROs, the number of participants who withdrew or died, according to 
treatment group. There was a good completion rate of CRFs and PROs across both treatment 
groups throughout the study period. In total 10 patients withdrew, 7 from Plaster Cast group 
and 3 from the Functional Brace group. There were 2 deaths, both in the Functional Brace 
group. Reasons for withdrawal are listed in  
Table 12 and these include clinician decision, patient decision and private treatment.  
 
Table 11: Details of available data at each follow-up time-point 
  Plaster Cast (n = 266) Functional Brace (n = 274) Total (n = 540) 
  n % n % n % 
8 weeks             
     CRF Completed 264 99.2% 273 99.6% 537 99.4% 
     PRO Completed 234 88.0% 241 88.0% 475 88.0% 
     Withdrawn
a
 6  2.3% 2  0.7% 8  1.5% 
     Died 0  0.0% 1  0.4% 1  0.2% 
     CRF Not Completed 1  0.4% 0  0.0% 1  0.2% 
     PRO Not Completed 26  9.8% 30 10.9% 56 10.4% 
3 month             
    PRO Completed 229 86.1% 245 89.4% 474 87.8% 
    Withdrawn
a
 7  2.6% 3  1.1% 10  1.9% 
    Died 0  0.0% 1  0.4% 1  0.2% 
    PRO Not Completed 30 11.3% 25  9.1% 55 10.2% 
6 month             
    PRO Completed 225 84.6% 238 86.9% 463 85.7% 
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    Withdrawn
a
 7  2.6% 3  1.1% 10  1.9% 
    Died 0  0.0% 2  0.7% 2  0.4% 
    PRO Not Completed 34 12.8% 31 11.3% 65 12.0% 
9 month             
    PRO Completed 244 91.7% 260 94.9% 504 93.3% 
    Withdrawn
a
 7  2.6% 3  1.1% 10  1.9% 
    Died 0  0.0% 2  0.7% 2  0.4% 
    PRO Not Completed 15  5.6% 9  3.3% 24  4.4% 
a 
Withdrawn participants and those who died are reported cumulatively and include the two participants who withdrew 
before receiving their treatment at baseline. See CONSORT flow diagram in 
 
Figure 16: EQ-5D Self Care from baseline pre-injury to 9 months. EQ-5D Self Care values range 






Figure 17: EQ-5D Usual Activities from baseline pre-injury to 9 months. EQ-5D Usual Activities 
values range from 1 to 5 with 1 indicating no problems 
 
 
Figure 18: EQ-5D Pain Discomfort from baseline pre-injury to 9 months. EQ-5D Pain Discomfort 






Figure 19: EQ-5D Anxiety Depression from baseline pre-injury to 9 months. EQ-5D Anxiety 
Depression values range from 1 to 5 with 1 indicating no problems 
. 
CRF: case report form; PRO: patient reported outcome  
 
Table 12: Number of withdrawals and reasons for withdrawal at follow-up time-pointsa. 
 Plaster Cast (n = 266) Functional Brace (n = 274) Total (n = 540) 
 n % n % n % 
8 weeks       
Withdrawn  6  2.3% 2  0.7% 8  1.5% 
Withdrawal Reason       
    Clinician decision 1  0.4% 0  0.0% 1  0.2% 
    Patient decision 4  1.5% 1  0.4% 5  0.9% 
    Private treatment 1  0.4% 1  0.4% 2  0.4% 
3 month       
Withdrawn  1  0.4% 1  0.4% 2  0.4% 
Withdrawal Reason       




   Private treatment  1  0.4% 0  0.0% 1  0.2% 
a Percentages are calculated out of total withdrawals. 
 
3.7 Analyses to address primary aims 
The primary outcome in this study is the ATRS measured at 9 months post injury as described 
in the Statistical Analysis Plan. 
ATRS was assessed at baseline (pre-injury), 8 weeks, 3 months, 6 months and 9 months after 
the tendon rupture. The mean ATRS score and SD for each treatment group at each time-point 
is provided in Table 13. The mean ATRS differences between the two treatment groups was 
estimated based on a linear mixed effects regression model both unadjusted and adjusted for 
the stratification factor recruitment centre, age, gender and baseline ATRS. The adjusted 
analysis was pre-specified as the principal analysis of the trial results.  
The adjusted analysis showed no statistically significant difference in ATRS between the two 
treatment groups at 9 months (-1.38; 95% CI -4.9 to 2.1). The 8-week follow up results show 
a statistically significant difference in the ATRS in favor of the Functional Brace group (5.75; 
95% CI 2.2 to 9.3), however this effect fades during the 9-month follow up. The ATRS 
adjusted mean difference between the two treatment groups is presented across time from the 
8-week to the 9-month follow-up in Error! Reference source not found.. 
Supplementary fully adjusted analyses were carried out accounting for further pre-defined 
prognostic variables and included recruitment centre, age, gender, baseline ATRS, diabetes 
and smoking status and are included in Table 14. These results showed a similar between-





Figure 3: ATRS adjusted mean difference between treatment groups pre-injury to 9 months 





Table 13: ATRS analysis at each time-point (ITT population) 
 
Plaster Cast Functional Brace 
Between - Group Difference 
(95% CI) 
 
 Mean (SD) n Mean (SD) n Unadjusted Adjustedb p-value 
Baseline 100.0 (96.5, 100)a 264 100.0 (94, 100)a 273    
8 week 35.3 (20.1) 234 40.3 (17.8) 240 4.98 (1.3, 8.7) 5.53 (2, 9.1) 0.002 
3 month 44.4 (21.1) 229 45.6 (20.4) 244 1.23 (-2.5, 4.9) 1.76 (-1.8, 5.3) 0.335 
6 month 63.9 (21.4) 224 63.5 (23) 235 -0.44 (-4.2, 3.3) 0.35 (-3.3, 4) 0.850 
9 month 74.4 (19.8) 244 72.8 (20.4) 259 -1.65 (-5.2, 1.9) -1.38 (-4.9, 2.1) 0.439 
 
a Median and Interquartile Range 
b Achilles Tendon Rupture Score (ATRS) analysis adjusted for recruitment centre, age, gender and baseline ATRS  





Complier Average Causal Effect Analysis 
 
Sensitivity analyses were conducted to explore the definition of compliance with treatment and 
to assess whether the primary analysis results were robust. Adherence to allocated treatment 
can affect the interpretation of the impact of what was offered to patients. This may be a 
particular issue in an ITT analysis as this includes all patients as they were expected to be 
treated and does not account for whether patients received or adhered to the intervention 
allocated to them.  
 
The number of participants compliant with the allocated treatment for the different periods 






Table 7 in Section 0. A CACE analysis was conducted to estimate the mean effect of treatment 
in compliers with treatment for 6 weeks or more (265, 96.7% in the Functional Brace group). 
The number of participants compliant with treatment for 4 weeks or more and 2 weeks or more 
were identical in the Functional Brace group (268, 97.8%) and hence CACE analysis was only 
conducted including patients compliant for 4 weeks or more.  
We estimated the CACE using the xtivreg and xtset commands in Stata software. The 
unadjusted and the adjusted analyses estimating the ITT effect and the CACE analysis effect 
are shown in Table 14. The unadjusted CACE estimate was marginally greater in modulus 
compared to the ITT (-1.70, 95% CI -5.3, 1.9), but this difference was small given the ATRS 
scoring scale. The adjusted CACE analysis showed similar results to the ITT population 
analysis (-1.17, 95% CI -4.5 to 2.1). 
 
Area Under the Curve  
A further analysis of the ATRS was conducted in order to explore recovery in the two 
treatment groups over time. This analysis shows a summary of the longitudinal data collected 
at all four time-points to a single value, the AUC. 39 Parameter estimates from the mixed 
effects models were used to calculate AUC from 8 week to the 9-month follow-up for a male 
participant of mean age (48.65 years). Results showing an overall estimate of recovery over 
time and a t-test comparison of the two treatment groups is presented in Table 14.  Higher 
AUCs indicate better overall functionality. Functional Brace group shows a better overall 
functionality than the Plaster Cast group, however the difference (-5.26; 95% CI -24.66 to 
14.14) was not statistically significant.  
 
Table 14: ATRS supplementary analyses 
Analysis (population) Time point Between - Group 
Difference (95% CI)  
p-value 
Unadjusted (ITT)b  9 month -1.65 (-5.2, 1.9 ) 0.367 
Adjusted (ITT) c 9 month -1.38 (-4.9, 2.1) 0.439 
Fully adjusted (ITT) d 9 month -1.15 (-4.7, 2.4) 0.520 
Unadjusted (CACE) b 9 month -1.70 (-5.3, 1.9) 0.349 
Adjusted (CACE) c 9 month -1.18 (-4.5, 2.1) 0.486 
AUC adjusted (ITT) c  8 week to 9 month -5.26 (-24.66, 14.14) 0.595 
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b Based on a mixed effects model analysis 
c Based on a mixed effects model adjusted for site, age, gender and baseline ATRS 
d Based on a mixed effects model adjusted for site, age, gender, baseline ATRS, diabetes and smoking status 
CI: confidence interval; CACE: Complier Average Causal Effect;  AUC = Area Under the Curve; ITT: Intention-
To-Treat 
 
Pre-specified subgroup analysis 
There were no pre-specified subgroups and therefore no subgroup analyses were conducted.  
3.8 Analyses to address secondary outcomes 
The secondary outcomes collected and analysed in the UKSTAR trial were EQ-5D-5L and 
complications evaluated at 8 weeks, 3, 6 and 9 months after the injury.  
EQ-5D-5L 
EQ-5D-5L was analysed as a continuous outcome using the utility score values from the 5-
level questions and based on the reported EQ VAS. Summary results for the EQ-5D utility 
score are reported in the Health Economics 4.1.3 and EQ-5D VAS are reported for each 
intervention group at each time point in Table 15 together with the unadjusted and adjusted 
mixed effects model estimates. The analysis for both EQ-5D utility score and EQ-5D VAS 
was adjusted for recruitment centre, age, gender and baseline EQ-5D pre-injury value and is 
presented graphically in  






Figure 5. Both EQ-5D scores present a trend of improvement over time. The EQ-5D utility 
score analysis showed a statistically significant difference between the two treatment groups 
at the 8-week follow-up in favour of the Functional Brace group (0.069; 95% CI 0.03 to 0.1) 
but this difference was no longer present by the 9-month post injury follow-up.  
 






Figure 5: EQ-5D VAS adjusted difference between treatment groups post injury baseline to 




Table 15: EQ-5D Utility and VAS results at 8, 3, 6 and 9 months post injury (ITT population) 
 Plaster Cast (n = 266) Functional Brace (n = 274) Between - Group Difference (95% CI)  
 Mean (SD) n Mean (SD) n Unadjusted Adjustedb p-value 
EQ-5D VASc        
     Baseline post injury 90.0 (80, 95)a 263 90.0 (80, 95)a 273 0.77 (-2.18, 3.72) 1.28 (-1.4, 3.97) 0.349 
     8 week 75.0 (60, 85)a 234 75.0 (65, 85)a 240 1.08 (-2.05, 4.2) 1.61 (-1.21, 4.43) 0.264 
     3 month 80.0 (65, 85)a 229 80.0 (65, 90)a 245 1.29 (-1.84, 4.42) 1.66 (-1.16, 4.48) 0.249 
     6 month 81.5 (70, 90)a 224 80.0 (70, 90)a 236 0.49 (-2.69, 3.66) 1.08 (-1.77, 3.93) 0.458 
     9 month 86.0 (80, 92)a 242 85.0 (75, 91)a 259 -0.76 (-3.8, 2.28) -0.56 (-3.32, 2.2) 0.693 
aMedian (Interquartile Range);  bAnalysis adjusted for site, age, gender and EQ-5D baseline pre-injury equivalent 




Sensitivity analyses were performed for the EQ-5D utility and VAS outcomes using CACE 
analysis and the AUC (Error! Reference source not found.). CACE was conducted using a 
similar approach as for the primary outcome ATRS and showed similar results to the EQ-5D 
ITT population analysis.  The AUC summary statistics were estimated for a male participant 
of mean age (48.65 years) calculated from baseline post injury to the 9 months post injury, 
with higher AUCs indicating better quality of life. 
 
Table 16: EQ-5D-5L sensitivity analyses 
Analysis (population) Time point Between - Group 
Difference (95% CI)  
p-value 
EQ-5D Utility    
  Adjusted (ITT) a 9 month -0.009 (-0.04, 0.03) 0.623 
  Adjusted (CACE) a 9 month -0.008 (-0.03, 0.02) 0.502 
  AUC adjusted (ITT) a  8 week to 9 month -0.20 (-0.4, 0.01)  0.056 
EQ-5D VAS    
  Adjusted (ITT) a 9 month -0.56 (-3.3, 2.2) 0.693 
  Adjusted (CACE) a 9 month -0.53 (-2.7, 1.7) 0.637 
  AUC adjusted (ITT) a b 8 week to 9 month -9.42 (-26.9, 8.1)  0.292 
 
a Based on a mixed effects model adjusted for site, age, gender and baseline ATRS  
b AUC: Area Under the Curve, higher AUC indicates better overall quality of life 




Complications were recorded from medical notes at the 8-week review and were patient-
reported at the 3-, 6- and 9-month follow up. The predefined complication categories were 
tendon re-rupture, DVT, PE, non-injurious falls, injurious falls, pain under the heel, 
numbness around the foot, pressure sores and additionally three categories were created 
based on the recorded text and included skin condition requiring medication, surgery related 




The rate of individual complications and the number of participants with one or more 
complications in each treatment group is presented overall from baseline to 9 months in Table 
17 and at every time point for the ITT population in Table 18. Fisher’s exact and chi-squared 
tests showed no statistically significant results when testing for associations between the 
treatment groups and each type of complication across time.  
 
Table 17: Analysis of secondary outcome complications from baseline to 9 months (ITT 
population)a 
 Plaster Cast (n = 266) Functional Brace (n = 274)  
 n % n % p-value 
  Tendon re-rupture 17 6.4% 13  4.7% 0.404 
  Deep Vein Thrombosis 3  1.1% 6  2.2% 0.505 
  Pulmonary Embolism 0  0.0% 2  0.7% 0.499 
  Fall - no injury 60 22.6% 53 19.3% 0.359 
  Fall - injury sustained 21  7.9% 24  8.8% 0.716 
  Pain under the heel 158 59.4% 180 65.7% 0.131 
  Numbness around the foot 108 40.6% 130 47.4% 0.109 
  Pressure sores 39 14.7% 51 18.6% 0.218 
a Numbers shown are complications reported at least once per participant 
 
Table 18: Complications recorded at the 8-week, 3-, 6- and 9-month follow-up (ITT 
population) 
 Plaster Cast (n = 
266) 
Functional Brace (n = 
274) 
 n % n % 
8 weeks     
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    Tendon re-rupture 3  1.1% 3  1.1% 
    Deep Vein Thrombosis 2  0.8% 6  2.2% 
    Pulmonary Embolism 0  0.0% 2  0.7% 
    Fall - no injury 26  9.8% 12  4.4% 
    Fall - injury 3  1.1% 6  2.2% 
   Pain under the heel 33 12.4% 48 17.5% 
    Numbness around the foot 24  9.0% 32 11.7% 
    Pressure sores 9  3.4% 9  3.3% 
   Skin condition requiring 
medication 
0  0.0% 4  1.5% 
   Surgery related to Achilles rupture 0  0.0% 3  1.1% 
   Fractured toe 1  0.4% 0  0.0% 
3 month     
   Tendon re-rupture 8  3.0% 4  1.5% 
   Deep Vein Thrombosis 2  0.8% 1  0.4% 
   Pulmonary Embolism 0  0.0% 2  0.7% 
   Fall  20  7.5% 15  5.5% 
   Fall - injury 7  2.6% 9  3.3% 
   Pain under the heel 125 47.0% 137 50.0% 
   Numbness around the foot 59 22.2% 79 28.8% 
   Pressure sores 23  8.6% 35 12.8% 
6 month     
   Tendon re-rupture 6  2.3% 6  2.2% 
   Deep Vein Thrombosis 0  0.0% 0  0.0% 




   Fall  19  7.1% 23  8.4% 
   Fall - injury 6  2.3% 11  4.0% 
   Pain under the heel 78 29.3% 82 29.9% 
   Numbness around the foot 54 20.3% 66 24.1% 
   Pressure sores 9  3.4% 15  5.5% 
9 month     
   Tendon re-rupture 0  0.0% 0  0.0% 
   Deep Vein Thrombosis 0  0.0% 0  0.0% 
   Pulmonary Embolism 0  0.0% 0  0.0% 
   Fall  16  6.0% 11  4.0% 
   Fall - injury 10  3.8% 5  1.8% 
   Pain under the heel 48 18.0% 66 24.1% 
   Numbness around the foot 51 19.2% 50 18.2% 





3.10 Ancillary analyses 
Following a presentation of the preliminary results, the Trial Steering Committee wished to 
explore where the apparent differences at 8 weeks in EQ-5D utility score came from. The 
individual domains in EQ-5D were explored using box-plots in Figure 15: EQ-5D Mobility 
from baseline pre-injury to 9 months. EQ-5D Mobility values range from 1 to 5 with 1 
indicating no problems 
 to Figure 19: EQ-5D Anxiety Depression from baseline pre-injury to 9 months. EQ-5D 
Anxiety Depression values range from 1 to 5 with 1 indicating no problems 
 as part of Appendix 3. The median score is marked with a triangle, whiskers are interquartile 
ranges and the individual dots and crosses mark the outliers. The differences at 8 weeks 
appear to lie in the ability to self-care and usual activities only.   
  
3.11 Adverse Events 
Foreseeable Adverse Events (AEs) were reported as complications in Section 3.8.  
Two deaths were reported in this study, one of which was a SAE. The SAE was due to a known 
lung cancer condition and was unrelated to the Achilles injury. The second death was due to a 
cardiac arrest following a bilateral PE and as judged by the investigators, was potentially 






4. Health Economics 
This section presents the results for the  health economic analyses comparing plaster cast to 
functional bracing. We compare: (i) missing data by treatment group; (ii) resource use and 
economic costs for different health and social care categories; (iii) distribution of the 
responses to the EQ-5D-5L questionnaires and EQ-5D-5L utility scores and; (iv) cost-
effectiveness results for the base-case and sensitivity analyses.  
 
4.1 Results of economic analysis 
Table 19 shows the degree of missing health economic data by treatment allocation and 
follow-up time point. The missing data pattern is non-monotonic, as individuals with missing 
data at one follow-up time point may return to the trial subsequently. For example, there are 
more missing EQ-5D data at 6 months than at 9 months post injury. A similar pattern can be 
observed for economic costs. It is worth noting that the lower number of participants with 
complete data for the entire duration of follow-up (baseline to 9 months post-injury) was due 
to a strict application of the term missing i.e. we considered a participant as having 
incomplete data if, for example, they responded positively to vising a GP surgery at 3 months 
but did not specify number of consultations, despite all other resource use items being 
completed.  However, for the cost-effectiveness analysis, imputation was not done at the 
aggregate level such that most of the data used for the analysis was based on actual 
participant responses.  
 
Table 19: Number and proportion of individuals with missing health economic data by 
treatment allocation 
Variable Description  Treatment group, missing 
values, n (%) 
Total, missing 
values, n (%) 
  Plaster cast 
(n=266) 
Functional brace 
(n = 274) 
 
eq5db EQ-5D index score pre injury 2 (0.75) 2 (0.73) 4 (0.74) 
eq5d0 EQ-5D index score post injury 2 (0.75) 1 (0.36) 3 (0.56) 
eq5d1 EQ-5D at 8 weeks 32 (12.06) 33 (12.04) 65 (12.04) 
eq5d2 EQ-5D at 3 months 37 (13.91) 29 (10.58) 66 (12.22) 
eq5d3 EQ-5D at 6 months 42 (15.79) 37 (13.5) 79 (14.63) 
eq5d4 EQ-5D at 9 months 22 (26) 15 (5.47) 37 (8.27) 
QALY QALYs generated from EQ-5D 
utility scores  
76 (28.57) 74 (27.01) 149 (27.78) 
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c0 Total resource use between 
baseline and 8 weeks post 
injury 
66 (24.8) 59 (21.53) 125 (23.15) 
c1 Total resource use between 8 
weeks and 3 months post injury 
59 (22.18) 47 (17.15) 106 (19.63) 
c2 Total resource use between 3 
and 6 months post injury 
56 (21.05) 48 (8.89) 104 (19.26) 
c3 Total resource use between 6 
and 9 months post injury 
31 (11.65) 18 (6.57) 49 (9.07) 
c4 Total resource use between 
baseline and 9 months post 
injury 
132 (49.62) 116 (42.34) 248 (45.93) 
QALY: quality adjusted life-year 
 
4.1.1 Health and social care resource use  
Table 28 (Appendix 4) shows resource use values for participants by trial group allocation, 
resource use category and follow-up period for complete cases. The resource values are 
presented for subcategories of resource use, including hospital inpatient and outpatient care, 
community health and social care, prescribed medications, equipment and aids, and 
productivity losses. 
In terms of specific resource use for plaster cast versus functional brace for all participants at 
the 8 week follow-up (Table 28, Appendix 4), notable differences were observed for: 
proportion prescribed anticoagulant as VTE prophylaxis treatment (0.72 vs 0.59; p=0.003), 
mean number of NHS outpatient orthopaedic visits (2.63 vs 1.80; p<0.001), mean number of 
NHS outpatient physiotherapy visits (0.23 vs 0.46; p=0.003), mean number of GP surgery 
visits (0.10 vs 0.19; p=0.028), and mean number of grab rail installations (0.05 vs 0; 
p=0.019). For all other resource use items, there were no noticeable differences between the 
trial groups.  
Between 8 week and 3 months post injury, for all participants (Table 28, Appendix 4) there 
were differences in resource use for plaster cast versus functional brace observed for: 
proportion of participants prescribed analgesics (0.11 vs 0.05; p=0.015) and proportion of 
participants prescribed other medications (0.02 vs 0; p=0.038). For all other resource use 
items, there were no noticeable differences between the trial groups.  
There were no significant differences in resource use for the Plaster Cast versus Functional 





4.1.2 Economic costs 
Table 20 summarises the total NHS and PSS costs associated with resource use during the 
trial period among complete cases, by cost category and follow-up period. The mean direct 
intervention costs were £35.71 for the Plaster Cast group compared with £108.64 for the 
Functional Brace group; the mean difference of £72.93 was statistically significant at the 5% 
level. The mean total NHS and PSS costs were significantly lower in the Functional Brace 
group between randomisation and 8-week post injury and between 8 weeks and 3 months 
post injury with mean between-group cost differences of £107.73 and £92.95, respectively. 
The mean total NHS and PSS cost throughout the entire follow-up period was £1182.64 for 
the Plaster Cast group and £1018.26 for the Functional Brace group; the mean between-group 
cost difference of £164.39 was not statistically significant at the 5% level.  
 
Table 20: NHS and personal social services costs for cases with complete resource use data 
by trial allocation, study period and cost category (£, 2017-18 prices) 







Plaster Cast Functional 
Brace 
   
Baseline to 8 weeks post injury – direct intervention costsc  (total , n = 497: Plaster Cast group; n = 256;  
Functional Brace group, n =256) 
Total direct intervention costs  35.71 (0.492) 108.64 (3.114) -72.93 <0.0001 -79.22 to 
(-66.64) 
Baseline to 8 weeks post injury – NHS PSS resource use (total , n = 432: Plaster cast group; n = 210;  
Functional brace group, n =222) 
Inpatient care 55.8 (28.382) 39.3 (22.163) 16.51 0.647 (-53.48 to 
86.49) 
Outpatient care 370.2 (15.114) 282.6 (15.078) 87.59 <0.0001 45.97 to 
129.21) 
Community care 9.66 (2.521) 28.94 (14.493) -19.28 0.191 (-47.64 to 
9.07) 
Medications  151.35 (9.334) 106.45 (8.701) 44.9 0 20.34 to 
69) 
Aids and adaptations 9.51 (0.842) 7.32 (0.568) 2.19 0.032 (0.20 to 
4.19) 
PSS 0.15 (0.151) 0 (0) 0.15 0.318 (-0.45 to 
0.14) 
Total NHS and PSS cost 596.67 (36.596) 464.61 
(32.946) 
-132.06 0.008 (-230.78 
to -33.35) 
Total Costs throughout first 8 
weeks (including direct 
intervention costs)d 












Plaster Cast Functional 
Brace 
   
8 weeks – 3months post injury (total , n = 434: Plaster Cast group; n = 207;  Functional Brace group, n 
=227) 
Inpatient care 61.69 (27.278) 4.74 (4.74) 56.95 0.041 (4.33 to 
109.57) 
Outpatient care 118.74 (9.948) 98.76 (7.608) 19.98 0.111 (-5.07 to 
45.03) 
Community care 31.96 (15.86) 19.89 (4.77) 12.07 0.339 (-20.69 to 
44.83) 
Medications  5.95 (3.359) 2.86 (2.133) 3.1 0.437 (-4.56 to 
10.75) 
Aids and adaptations 1.65 (0.359) 0.75 (0.261) 0.9 0.044 (0.014 to 
1.78) 
PSS 0 (0) 0.04 (0.04) -0.04 0.318 (-0.12 to 
0.039) 
Total NHS and PSS cost 220.00 (36.662) 127.04 
(12.333) 
92.95 0.017 (14.80 to 
171.11) 
3 – 6 months post injury (total , n = 436: Plaster Cast group; n = 210;  Functional Brace group, n =226) 
Inpatient care 21.08 (16.736) 43.94 (22.392) -22.86 0.414 (-80.61 to 
34.90) 
Outpatient care 128.56 (11.731) 142.56 
(13.215) 
-14 0.429 (-47.66 to 
19.67) 
Community care 33.56 (2.617) 27.75 (5.679) 5.812 0.376 (-19.98 to 
31.60) 
Medications  0 (0) 1.51 (1.015) -1.51 0.138 (-3.56 to 
0.54) 
Aids and adaptations 1.02 (0.472) 1.03 (0.534) -0.01 0.989 (-1.38 to 
1.36) 
PSS 0.49 (0.491) 0 (0) 0.49 0.318 (-0.42 to 
1.40) 
Total NHS and PSS cost 184.70 (26.350) 216.78 
(29.988) 
-32.07 0.422 (-108.74 
to 44.58) 
6 – 9 months post injury (total , n = 491: Plaster Cast group; n = 235;  Functional Brace group, n =256) 




Outpatient care 76.44 (22.253) 65.98 (9.884) 10.46 0.668 (-39.34 to 
60.26) 
Community care 14.03 (4.022) 17.302 (7.197) -3.27 0.691 (-19.78 to 
13.24) 
Medications  0.33 (0.228) 0.13 (0.058) 0.2 0.396 (-0.26 to 
0.66) 
Aids and adaptations 0.36 (0.217) 0.08 (0.052) 0.28 0.214 (-0.15 to 
0.71) 
PSS 0.11 (0.11) 0 (0) 0.11 0.318 (-0.10 to 
0.32) 
Total NHS and PSS cost 97.21 (23.666) 128.94 (46.80) -31.73 0.543 (-127.40 
to 63.94) 











Plaster Cast Functional 
Brace 
   




Inpatient care 162.29 (85.042) 45.43 (24.373) 116.86 0.188 (-62.66 to 
296.38) 
Outpatient care 722.78 (39.326) 653.42 
(40.288) 
69.36 0.219 (-38.61 to 
177.33) 
Community care 103.22 (33.32) 91.18 (22.809) 12.04 0.766 (-67.72 to 
91.80) 
Medications  146.41 (11.364) 112.61 
(10.884) 
33.8 0.033 (-2.66 to 
64.94) 
Aids and adaptations 11.75 (1.331) 9.16 (1.127) 2.59 0.139 (-0.71 to 
5.88) 
PSS 0.24 (0.236) 0 (0) 0.24 0.319 (-0.22 to 
0.70) 
Total NHS and PSS costs 





164.39 0.203 (-95.75 to 
424.52) 
a p-value calculated using the student’s t-test, two-tail unequal variance  
b Non-parametric bootstrap estimation suing 1000 replications 
c Time horizon for calculating total direct intervention costs was 8 weeks in order to capture costs associated 
with any changes required to either plaster cast or functional bracing (e.g. plaster cast changes)  
d Total costs throughout first 8 weeks calculated based on total sample size of 415: Plaster cast, n=200; 
Functional brace, n=215) i.e. cases with complete intervention and resource use costs at 8 weeks. 
PSS: Personal social services 
94 
 
4.1.3 Health outcomes 
The distribution of the responses to the EQ-5D-5L questionnaires by trial group and 
assessment point is presented in Table 21 and Table 22 for all participants. Table 21 shows 
that there were no significant differences in the proportions of individuals reporting 
suboptimal health (i.e. any functional (below level 1) impairment) within dimensions 
between the two treatment groups at each time point. The mean EQ-5D utility score was 
significantly lower at 8 weeks post injury in the Functional Brace group (0.588 versus 0.655; 
p<0.0001) amongst complete cases. However, there were no statistically significant 
differences in EQ-5D utility scores between the treatment groups at any other follow-up time-
point. There were no statistically significant differences in the Visual Analogue Scale scores 







Table 21: Distribution of EQ-5D-5L responses by trial group 
   
Pre-injury Baseline Post injury Baseline 8-week post- injury 3-months post injury 6-months post injury 9-months post injury 
   




















































Level 1 243 (91.4%) 247 (90.2%) 1 (0.4%) 1 (0.4%) 24 (9.0%) 34 (12.4%) 24 (9.0%) 34 (12.4%) 94 (35.3%) 103 (37.6%) 143 (53.8%) 148 (54.0%) 
Level 2 10 (3.8%) 14 (5.1%) 10 (3.8%) 11 (4.0%) 63 (23.7%) 88 (32.1%) 90 (33.8%) 101 (36.9%) 89 (33.5%) 85 (31.0%) 74 (27.8%) 80 (29.2%) 
Level 3 6 (2.3%) 8 (2.9%) 51 (19.2%) 64 (23.4%) 92 (34.6%) 100 (36.5%) 89 (33.5%) 90 (32.9%) 40 (15.0%) 40 (14.6%) 22 (8.3%) 28 (10.2%) 
Level 4 3 (1.1%) 3 (1.1%) 103 (38.7%) 108 (39.4%) 41 (15.4%) 22 (8.0%) 19 (7.1%) 17 (6.2%) 1 (0.4%) 9 (3.3%) 4 (1.5%) 3 (1.1%) 
Level 5 2 (0.8%) 0 99 (37.2%) 88 (32.1 %) 14 (5.3%) 1 (0.4%) 7 (2.6%) 3 (1.1 %) 0 
 
1 (0.4%) 0 
Missing 2 (0.8%) 2 (0.7%) 2 (0.8) 1 (0.4%) 32 (12.0%) 33 (12.0%) 37 (13.9%) 29 (10.6%) 42 (15.8%) 37 (13.5%) 22 (8.3%) 15 (5.5%) 
Sub-optimal 21 (7.9%) 25 (9.1%) 264 
(99.25%) 
273 (99.6 %) 210 (78.9%) 207 (75.5%) 205 (77.1%) 211 (77.0%) 130 (48.9%) 134 (48.9%) 101 (38.0%) 111 (40.5%) 
P-value1  0.877 
 








   
  







Level 1 254 (95.5%) 265 (96.7%) 35 (13.2%) 45 (16.4%) 114 (42.9%) 131 (47.8%) 169 (63.5%) 192 (70.1%) 204 (76.7%) 207 (75.6%) 230 (86.5%) 242 (88.3%) 
Level 2 7 (2.6%) 6 (2.2%) 68 (25.6%) 51 (18.6%) 74 (27.8%) 81 (29.6%) 38 (14.3%) 36 (13.1%) 18 (6.8%) 23 (8.4%) 10 (3.8%) 17 (6.2%) 
Level 3 1 (0.4%) 1 (0.4%) 107 (40.2%) 117 (42.7) 41 (15.4%) 26 (9.5%) 19 (7.1%) 15 (5.5%) 2 (0.8%) 4 (1.5%) 3 (1.1%) 1 (0.4%) 
Level 4 2 (0.8%) 0 49 (18.4%) 55 (20.1%) 5 (1.9%) 3 (1.1%) 2 (0.8%) 2 (0.7%) 0 3 (1.1%) 1 (0.4%) 0 
Level 5 0 0 5 (1.9%) 5 (1.8%) 0 0 1 (0.4%) 0 0 0 0 0 
Missing 2 (0.8%) 2 (0.7%) 2 (0.8%) 1 (0.4%) 32 (12.0%) 33 (12.0%) 37 (13.9%) 29 (10.6%) 42 (15.8%) 37 (13.5%) 22 (8.3%) 14 (5.1%) 
Sub-optimal 10 (3.8%) 7 (2.6%) 229 (86.1%) 227 (82.9%) 120 (45.1%) 110 (40.1%) 60 (22.6%) 53 (19.3%) 20 (7.5%) 30 (11.0%) 14 (5.3%) 18 (6.6%) 
P-value1 0.725 
 








    
  











Level 1 245 (92.1%) 253 (92.3%) 3 (1.1%) 1 (0.4%) 18 (6.8%) 19 (6.9%) 26 (9.8%) 40 (14.6%) 80 (30.1%) 96 (35.0%) 141 (53.0%) 134 (48.9%) 
Level 2 10 (3.8%) 10 (3.7%) 13 (4.9%) 13 (4.7%) 59 (22.2%) 89 (32.5%) 92 (34.6%) 100 (36.5%) 132 (38.4%) 91 (33.2%) 80 (30.1%) 85 (31.0%) 
Level 3 5 (1.9%) 6 (2.2%) 50 (18.8%) 73 (26.6%) 83 (31.2%) 85 (31.0%) 74 (27.8%) 76 (27.7%) 38 (14.3%) 34 (12.4%) 19 (7.1%) 33 (12.0%) 
Level 4 2 (0.8%) 2 (0.7%) 100 (37.6%) 102 (37.2%) 51 (19.2%) 30 (10.9%) 25 (9.4%) 17 (6.2%) 3 (1.1%) 13 (4.7%) 2 (0.8%) 3 (1.1%) 
Level 5 2 (0.8%) 1 (0.4%) 98 (36.8%) 84 (30.7%) 23 (8.6%) 18 (6.6%) 12 (4.5%) 12 (4.4%) 1 (0.4%) 3 (1.1%) 2 (0.8%) 5 (1.8%) 
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Pre-injury Baseline Post injury Baseline 8-week post- injury 3-months post injury 6-months post injury 9-months post injury 
   






























Missing 2 (0.8%) 2 (0.7%) 2 (0.8%) 1 (0.7%) 32 (12.0%) 33 (12.0%) 37 (13.9%) 29 (10.6%) 42 (15.8%) 37 (13.5%) 22 (8.3%) 14 (5.1%) 
Sub-optimal 19 (7.1%) 19 (7.1%) 261 (98.1%) 273 (99.3%) 216 (81.2%) 222 (81.0%) 203 (76.3%) 205 (74.8%) 144 (54.1%) 141 (51.5%) 103 (38.7%) 126 (46.0%) 
P-value1 0.995 
 






    
  
        











Level 1 226 (85.0%) 226 (82.5%) 18 (6.8%) 13 (4.7%) 63 (23.7%) 74 (27.0%) 23 (8.7%) 33 (12.0%) 56 (21.1%) 61 (22.3%) 87 (32.7%) 86 (31.3%) 
Level 2 24 (9.0%) 33 (12.0%) 86 (32.3%) 98 (35.8%) 125 (47.0%) 112 (40.9%) 139 (52.3%) 139 (50.7%) 126 (47.4%) 134 (48.9%) 124 (46.6%) 140 (51.1%) 
Level 3 7 (2.6%) 10 (3.7%) 102 (38.4%) 113 (41.2%) 38 (14.3%) 52 (19.0%) 61 (22.9%) 68 (24.8%) 38 (14.3%) 35 (12.8%) 29 (10.9%) 29 (10.6%) 
Level 4 4 (1.5%) 1 (0.4%) 46 (17.3%) 40 (14.6%) 6 (2.3%) 3 (1.1%) 3 (1.1%) 4 (1.5%) 4 (1.5%) 7 (2.6%) 4 (1.5%) 5 (1.8%) 
Level 5 3 (1.1%) 2 (0.7%) 12 (4.5%) 9 (3.3%) 2 (0.8%) 0 3 (1.1%) 1 (0.4%) 0 0 0 0 
Missing 2 (0.8%) 2 (0.7%) 2 (0.8%) 1 (0.4%) 32 (12.0%) 33 (12.0%) 37 (13.9%) 29 (10.6%) 42 (15.8%) 37 (13.5%) 22 (8.3%) 14 (5.1%) 
Sub-optimal 38 (14.3%) 46 (16.8%) 246 (92.5%) 260 (94.9%) 171 (64.3%) 167 (60.9%) 206 (77.4%) 212 (77.4%) 168 (63.2%) 176 (64.2%) 157 (59.0%) 174 (63.5%) 
P-value1 0.725 
 






    
  













Level 1 231 (86.8%) 240 (87.6%) 145 (54.5%) 158 (57.7%) 141 (53.0%) 158 (57.7%) 138 (51.9%) 149 (54.4%) 155 (58.3%) 174 (63.5%) 190 (71.4%) 190 (69.3%) 
Level 2 20 (7.5%) 20 (7.3%) 69 (25.9%) 70 (25.5%) 57 (21.4%) 59 (21.5%) 59 (22.2%) 69 (25.2%) 49 (18.4%) 38 (13.9%) 41 (15.4%) 55 (20.1%) 
Level 3 9 (3.4%) 11 (4.0%) 39 (14.7%) 38 (13.9%) 32 (12.0%) 22 (8.0%) 26 (9.8%) 23 (8.4%) 17 (6.4%) 21 (7.7%) 7 (2.6%) 13 (4.7%) 
Level 4 2 (0.8%) 1 (0.4%) 9 (3.4%) 5 (1.8%) 3 (1.1%) 2 (0.7%) 3 (1.1%) 3 (1.1%) 3 (1.1%) 3 (1.1%) 5 (1.9%) 1 (0.4%) 
Level 5 2 (0.8%) 0 2 (0.8%) 2 (0.7%) 1 (0.4%) 0 3 (1.1%) 1 (0.4%) 0 1 (0.4%) 1 (0.4%) 1 (0.4%) 
Missing 2 (0.8%) 2 (0.7%) 2 (0.8%) 2 (0.7%) 32 (12.0%) 33 (12.0%) 37 (13.9%) 29 (10.6%) 42 (15.8%) 37 (13.5%) 22 (8.3%) 14 (5.1%) 
Sub-optimal 33 (12.4%) 32 (11.7%) 119 (44.7%) 115 (42.0%)   91 (34.2%) 96 (35.0%) 69 (25.9%) 63 (23.0%) 54 (20.3%) 70 (25.6%) 
P-value1 0.966 
 






               






Table 22: Patient-reported EQ-5D-5L utility scores and VAS results by treatment group and time-point 
 Plaster Cast (n=266) Functional Brace (n=274) Plaster Cast versus 
Functional Brace 
Between - Group Difference 
(95% CIa) 








Mean (SE) Mean unadjusted 
difference (bootstrap 
95% CI) 
Adjustedb  P-value 
EQ-5D-5L utility scores 
Baseline post injury 264 0.243 (0.017) 273 0.285 (0.017) -0.042  (-0.09 to 0.006) 0.041 (0.01, 0.07) 0.017 
8 weeks 234 0.588 (0.015) 241 0.655 (0.012) -0.066 (-0.102 to -0.031) 0.069 (0.03, 0.1) <0.0001 
3 months 229 0.638 (0.014) 245 0.669 (0.012) -0.031 (-0.070 to 0.002) 0.035 (0, 0.07) 0.056 
6 months 224 0.766 (0.010) 237 0.757 (0.011) 0.009 (-0.021 to 0.039) -0.002 (-0.04, 
0.03) 
0.916 




Baseline post injury 263 90.0 (80, 95)b 263 90.0 (80, 95)c 0.77 (-2.18, 3.72) 1.28 (-1.4, 3.97) 0.349 
8 weeks 234 75.0 (60, 85)b 234 75.0 (65, 85)c 1.08 (-2.05, 4.2) 1.61 (-1.21, 4.43) 0.264 
3 months 229 80.0 (65, 85)b 229 80.0 (65, 90)c 1.29 (-1.84, 4.42) 1.66 (-1.16, 4.48) 0.249 
6 months 224 81.5 (70, 90)b 224 80.0 (70, 90)c 0.49 (-2.69, 3.66) 1.08 (-1.77, 3.93) 0.458 
9 months 242 86.0 (80, 92)b 242 85.0 (75, 91)c -0.76 (-3.8, 2.28) -0.56 (-3.32, 2.2) 0.693 
a CI: confidence interval 
b Analysis adjusted for site, age, gender and EQ-5D baseline pre-injury equivalent. Given the pattern of results, Plaster Cast has been selected as the referent and Functional Brace as the 
comparator in the estimation of adjusted values. 
c Median (Interquartile Range) 
d VAS: Visual Analogue Scale
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4.1.4 Cost-effectiveness results 
The cost-effectiveness results are presented in Table 23 with Plaster Cast selected as the 
referent and Functional Brace as the comparator, i.e. functional brace minus plaster cast, for 
the estimation of ICER values. The analytic time horizon covers the entire 9-month post-
injury follow-up period of the trial.  The joint distribution of costs and outcomes for the base-
case analysis and sensitivity analyses are graphically represented in Figure 6 to Figure 13. 
 
Base case analysis 
Patients in the Functional Brace group experienced a non-statistically significant increase in 
QALYs in the base case (0.015 QALYs, 95% CI: -0.0013 to 0.030) over the 9-month follow-
up period. Mean NHS and PSS costs were also lower in the Functional Brace group [mean 
cost difference: -£103 (95% CI: -289 to 84)]. The ICER for the base-case analysis indicates 
that functional bracing is the dominant procedure as average costs for this intervention were 
lower whilst average benefits were greater than those for plaster cast. 
Assuming cost-effectiveness thresholds of £15000 per QALY, £20000 per QALY and 
£30000 per QALY, respectively, the probability of cost-effectiveness for functional bracing 
ranged from 0.96 to 0.97, whilst the NMB associated with functional bracing was positive 
(Table 23).  
 
Sensitivity analyses 
Comparing mean costs and QALY estimates using different analytical scenarios (complete 
case, societal perspective and CACE population) revealed that the cost-effectiveness results 
generally supported the base case finding, with the exception of the sensitivity analysis that 
adopted a societal perspective. For the societal perspective, mean costs were higher in the 
Functional Brace group (£248, 94% CI: -476 to 972). However, the QALY results followed 
the same pattern as that for the base case analysis and indicated that participants in the 
Functional Brace group experienced a non-statistically significant increase in QALYs over 
the 9-month follow-up period (0.015 QALYs, 95%CI: -0.0042 to 0.031). The probability of 
cost-effectiveness of functional brace declined to a range of 0.50 to 0.69 at cost-effectiveness 




the mixed effects model followed a similar pattern to that of the base case (imputed) model: 
Patients in the Functional Brace group experienced a non-statistically significant increase in 
QALYs (0.014 QALYs, 95% CI: -0.0018 to 0.031) over the 9-month follow-up period. Mean 
NHS and PSS costs were also lower in the Functional Brace group [mean cost difference: -
£135 (95% CI: -342 to 71)]. 
 
4.1.5 Long-term economic modelling 
The protocol allowed for decision-analytic modelling to estimate the longer-term cost-
effectiveness of functional bracing or plaster cast. However, we note that cost and health 
utility values started to converge from the 3-month follow-up time-point and converged at 
subsequent time points, even though functional brace was cost-effective over the entire 
follow-up period. It was therefore concluded that longer-term extrapolation of cost-
effectiveness of functional is highly unlikely to be meaningful. Furthermore, we did not 
identify external studies that compared differences in economic costs, functional outcomes or 
health-related quality of life beyond 9 months post injury in non-surgical patients treated with 
a plaster cast or functional brace. This lack of data needed to parameterize a model further 









Table 23: Cost-effectiveness, cost/QALY (£, 2017): functional brace compared to plaster cast 
Scenario Treatment group, 
mean (SE) Cost 
Incremental 
cost 
 (95% CI) 
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(-0.0013 to 
0.030) 
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(-0.0035 to 
0.037) 
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273.86 to     
89.44) 
45.09 (0.72) 44.30 
(0.73) 
0.78 (-1.12 to    
2.69) 










*ICER: Incremental cost-effectiveness ratio. Given the pattern of results, Plaster Cast has been selected as the referent and Functional Brace as the comparator, i.e. functional brace minus 
plaster cast, for the estimation of ICER values. Dominance indicates average costs were less and average benefit greater for functional brace vs. plaster cast 
P1, P2, P3: probability cost-effective if cost-effectiveness threshold set at £15,000/QALY, £20,000/QALY or £30,000/QALY, respectively with the exception of the sensitivity analysis using 
ATRS as the health outcome measure of interest. In the latter  case  P1, P2, P3 refer to probability of cost-effectiveness if cost-effectiveness threshold arbitrarily set at £100; £300  and £500 per 
unit gain in ATRS score 
NMB1, NMB2,NMB3: net monetary benefit if cost-effectiveness threshold set at £15,000/QALY, £20,000/QALY or £30,000/QALY, respectively with the exception of the sensitivity analysis 
using ATRS as the health outcome measure of interest. In the latter  case  NMB1, NMB2,NMB3 refer to net monetary benefit if cost-effectiveness threshold arbitrarily set at £100; £300  and 
£500 per unit gain in ATRS score 
4 CACE Complier Average Causal Effect 
5 ATRS  (Achilles Tendon Rupture Score) range from 0 to 100 with higher scores indicating better outcome 
6 CI: confidence interval 












Figure 6: Cost-effectiveness scatterplot at 9 months for base case analysis (NHS and 







Figure 7: Cost-effectiveness acceptability curve at 9 months for base case analysis (NHS and 




Figure 8: Cost-effectiveness scatterplot at 9months for complete cases (NHS and personal 






























Figure 9: Cost-effectiveness acceptability curve for complete cases (NHS and personal social 
perspective, intention-to-treat analysis) 
 
 

































Figure 11: Cost-effectiveness acceptability curve for societal perspective (imputed, 
intention-to-treat analysis) 
 
Figure 12: Cost-effectiveness scatterplot for complier average causal effect population, 































Figure 13: Cost-effectiveness acceptability curve for complier average causal effect 



































A total of 375 patients were screened but found to be ineligible for the trial. The most 
common reason for patients being ineligible (n=155) was that they presented more than 14 
days after their Achilles tendon injury. Late presentation after an Achilles tendon rupture is 
not uncommon. Although the patient may have severe pain when the tendon ruptures, this 
acute pain usually settles quickly and the patient can often put weight through their leg, albeit 
without being able to walk normally. Some patients feel that they would not be able to walk 
at all if they had suffered a ‘serious’ injury and therefore continue to try to mobilise on their 
leg before eventually seeking treatment some time later, when their limp has not improved. 
The cut-off of 14 days used to define an ‘acute’ rupture is somewhat arbitrary, but in keeping 
with definitions used in previous research into this injury. Patients presenting at later times 
may have partial or complete healing of the tendon, but often with tendon lengthening which 
restricts their function. The treatment of late presentation injuries is not straightforward and 
often requires surgical intervention, therefore these patients were excluded from this trial of 
acute non-operative management.  
 
The second common reason for patients being ineligible (n=120) was that they chose to have 
surgery. This is perhaps fewer than was anticipated when the UKSTAR trial was designed 
and, to some degree, accounts for the faster than expected rate of recruitment. However, it is 
in keeping with the worldwide trend towards non-operative treatment of acute rupture of the 
Achilles tendon, as per the recent evidence base which suggests little functional advantage to 
surgery. 8, 9  
 
Only 46 patients were excluded because they were unable to adhere to trial procedures or 
complete questionnaires, most commonly because they could not read written English, as 
used in the follow-up questionnaires. Thirty-seven patients were excluded because they had 
suffered a previous Achilles tendon injury, which was likely to have affected their baseline, 
pre-injury function. Achilles tendon rupture is very rare in children and hence it is not 
surprising that only three patients were excluded as being less than 16 years of age. The 
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remaining 14 patients were excluded by recruitment centres under the heading of ‘other’; we 
did not record details of these individual cases.   
 
Of the 1076 potentially eligible patients screened across the 39 recruitment centres, 540 
consented to enter the trial. Ninety nine patients were not approached about the trial because 
there was no research associate available to discuss the trial (n=97), usually because the 
patient presented at the weekend, or because there was no functional brace available at the 
time of presentation (n=2). A further 50 patients were not offered the opportunity to take part 
in the trial due to a clinician decision. In some cases, there were specific reasons given for 
this decision, for example “active treatment of a local skin lesions precluding the use of a 
cast”, but in other cases the clinician did not provide a reason. Therefore, a total of 149 
potentially eligible patients were never offered the opportunity to take part in the trial. This 
reduced the number of participants but is unlikely to have caused a selection bias.  
 
Of the 927 patients who had the opportunity to take part, 385 declined. Patients may decline 
to take part in a trial for various reasons. Those who do not want to be part of any research – 
often because of the perception, of indeed the reality, of filling out extra, onerous 
questionnaires – are unlikely to adversely affect the trial in terms of the difference between 
treatment groups. However, those who decline because of a preference for one treatment over 
another do create a selection bias. In this trial, it is reassuring that 542 of the 927 patients who 
were offered the opportunity to take part in the trial (58%) agreed to participate.  
 
5.2 Participants and interventions 
The two groups of participants were well balanced in terms of baseline, pre-injury 
characteristics.  
 
In keeping with the epidemiology of Achilles tendon rupture, there were more men aged 30-
40 years, whereas women were a little older at the time of their injury, being 40-60 years 
most commonly. Sports accounted for the great majority of ruptures (70.4%) and relatively 




3.9% were taking steroids, these being associated with an increased risk of tendon rupture. 
Only 3.7% declared a pre-existing Achilles tendinopathy, which also fits with the literature in 
that most patients do not have symptoms before their tendon rupture. This is despite the fact 
that histological studies indicate that there are almost always degenerative changes present in 
biopsies taken from tendons immediately after injury. 4, 5 
The median pre-injury ATRS score was 100 in both groups, indicating normal Achilles 
function. Similarly, the median EQ-5D utility score was 1, indicting perfect health. This, and 
the fact that the large majority of participants were employed or self-employed, suggests that 
most Achilles ruptures affect working-age people with good pre-injury health. However, the 
characteristics of the participants reflects the epidemiology in that Achilles rupture affects all 
age groups with both men and women in their 80’s represented within the trial. Overall the 
participants in the trial are representative of the previously reported demographics of patients 
with this injury. 
We anticipated some cross-over between treatment groups following the random allocation, 
but in fact this was relatively uncommon. Only one participant decided to have a cast, having 
been allocated a functional brace. Thirteen participants decided to change to a functional 
brace, having been allocated a cast, which may reflect the perception that the brace made 
mobilisation easier. However, the numbers were small and we did not formally investigate 
the qualitative aspects of the decision to change treatment. Two further participants withdrew 
from the trial immediately after randomisation and seven others crossed over treatment 
groups for what were described as clinical or unknown reasons. Given the small number of 
cross-overs at baseline, these are very unlikely to have influenced the results of the trial. 
In terms of compliance with treatment once implemented, the trial protocol stipulated that 
patients would be deemed compliant if they maintained their allocated treatment for a 
minimum of six weeks. The choice of six weeks reflects the fact that this was the time at 
which weight-bearing would usually be permitted for those patients in a cast, those in a 
functional brace generally being fully weight-bearing from the outset. Overall, 88% of 
participants were fully compliant. However, compliance was higher in the Functional Brace 
group (97%) compared to the Plaster Cast group (80%). This may reflect the participants 
desire to have the cast removed as soon as possible (most of these participants then using a 
functional brace for a further two weeks or more) but we did not interview participants 
regarding the reasons why they changed treatment after six weeks. 
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Some patients did of course change treatment before six weeks, having initially accepted their 
allocated intervention. This was more common in the plaster cast group where 11.3% 
changed to a functional brace, versus 0.4% allocated a functional brace who changed to a 
plaster cast. This may also suggest that the functional brace was preferred but, although we 
asked these participants if they or the clinician treating them chose/recommended changing 
treatment, we were not able to formally explore the reasons behind the decision to change 
treatment. An additional 3% of participants chose to have surgery before six weeks; 1.9% in 
the plaster cast group and 1.1% in the functional brace group. In some cases, these 
participants described a further fall/injury to their tendon. However, we have not reported 
these as ‘re-ruptures’ of the tendon on the basis that the tendon was unlikely to be healed in 
the first place, before six weeks.  
One other notable element of the participants’ treatment beyond the allocation to functional 
brace or cast, was the use of VTE prophylaxis. Patients with Achilles tendon rupture are at 
increased risk of VTE, as the injury defunctions the triceps surae muscles which are an 
important part calf muscle pump which helps return of venous blood to the heart. In the 
Plaster Cast group, 70% of patients had VTE prophylaxis, most commonly with self-
administered low molecular weight heparin injections. Fewer patients (58%) had VTE 
prophylaxis in the Functional Brace group. This difference may reflect the belief that patients 
who are able to fully weight-bear in a functional brace are at lower risk of VTE than those 
with restricted weight-bearing in a cast, but this trial was not designed to address questions 
related to the management of VTE. 
 
5.3 Results 
In total, 93.3% of participants completed the primary outcome measure at 9 months after their 
Achilles tendon rupture. This included 91.7% in the Plaster Cast group and 94.9% in the 
Functional Brace group. Therefore, loss to follow-up was considerably less than the 20% 
accounted for in the trial design which, alongside the fact that the trial was able to recruit 
more patients than the minimum of 330 required by the sample size calculation, ensures that 
the trial had considerably greater than 90% power. 
Follow-up was also good at other time-points with 88%, 88% and 86% of participants 




5.3.1 Primary Outcome 
The adjusted ITT analysis showed no statistically significant difference in ATRS between the 
two treatment groups at the primary end-point of 9-month post injury (-1.38; 95% CI -4.9 to 
2.1). 
There was a statistically significant difference in the ATRS at 8 week in favour of the 
Functional Brace group (5.75; 95% CI 2.2 to 9.3), although this difference is of borderline 
clinical importance. However, any benefit to functional bracing was not evident later in the 
participants’ recovery with very similar ATRS scores at three and six, as well as nine months. 
As expected, given the relatively small number of patients who were non-compliant with 
treatment, the secondary sensitivity analysis, using adjusted Complier Average Causal Effect, 
showed the same pattern. There was no evidence of a difference at 9 months post injury (-
1.17, 95% CI -4.5 to 2.1). Nor was there any evidence of a difference on the other pre-
specified analysis of overall ATRS scores (AUC) over the full period of follow-up. 
 
5.3.2 Secondary Outcomes 
The analysis of patient-reported health-related quality of life (EQ-5D utility score) provides 
powerful corroborating evidence in support of the findings using the ATRS. There was a 
statistically significant and clinically relevant difference in favour of functional bracing at 8 
weeks (0.069; 95% CI 0.03 to 0.1). A breakdown of the EQ-5D by domain of health showed 
that this differences at 8 weeks lies in the ability to ‘self-care’ and ‘usual activities’.  This 
difference in EQ-5D utility scores was of borderline statistical significance (0.035 95% CI 0 
to 0.07) at 3 months but there was no evidence of a difference at any subsequent time-point. 
There was no evidence of a difference in EQ-5D VAS scores. 
The trial was designed to compare patient-centred outcomes between participants randomly 
allocated to a plaster cast versus a functional brace. However, the safety profile of the 
functional brace was another important consideration. Specifically, if the risk of re-rupture of 
the tendon was higher in those patients allowed to fully weight-bear in a functional brace, this 
would influence decision-making in this area, even when patient-reported outcomes were 
similar. Interestingly, the risk of re-rupture was generally lower than reported in the literature, 
with a total of 17 (6.4%) cases in the Plaster Cast group and 13 (4.7%) in the Functional 
Brace group. None of the re-ruptures occurred more than six months after the injury. 
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There was no evidence of associations between treatment group and any other type of 
complication, with the exception of non-injurious falls, which were more common in the 
Plaster Cast group (p=0.015) 
5.4 Health economic evaluation 
The mean direct intervention costs were £36 for the Plaster Cast group compared with £109 
for the Functional Brace group. The greater up-front cost of the functional brace (mean 
difference £73) was statistically significant. However, by 8 weeks this difference had 
reversed such that the mean total NHS and PSS costs were significantly lower in the 
Functional Brace group. The difference being driven mostly by the increased number of 
outpatient appointments required in the Plaster Cast group. 
This is an important finding as it will reassure the finance teams in Trauma and Orthopaedic 
Departments that, despite the extra initial cost of a functional brace, they will reduce their 
overall costs when treating patients with an Achilles tendon rupture.  
The mean total NHS and PSS cost throughout the entire follow-up period was £1183 for the 
Plaster Cast group and £1018 for the Functional Brace group. Although the functional 
bracing was marginally cheaper, the mean between-group cost difference of £164 was not 
statistically significant. 
In terms of health-related quality of life, the mean QALY value was, on average, marginally 
higher for the Functional Brace group amongst complete cases and in the sensitivity analyses, 
although this mean QALY difference was not statistically significant. 
Therefore, since the Functional Brace group incurred slightly lower costs and achieved 
slightly better quality of life over the course of the study, in health economic terms, 
functional bracing is the dominant intervention.  
In summary, the health economic evaluation indicates that functional bracing is very likely to 
be cost-effective. 
5.5 Limitations 
A concern at the start of the study was that patients would not be willing to take part in a trial 
comparing two distinct interventions which needed to be worn for a prolonged period of time. 




research project. These patients, whilst undoubtedly affecting the external validity of the trial, 
are unlikely to create a selection bias when comparing the two interventions. By contrast, 
those who declined because of a preference for one treatment over another do create a 
selection bias. However, in total, 542 of the 927 patients who were offered the opportunity to 
take part in the trial (58%) agreed to participate, so we can be confident that the participants 
in the trial are broadly representative of the population of patients having non-operative 
treatment for an acute rupture of the Achilles tendon. 
A further anticipated limitation was cross-over from the allocated trial treatment, and indeed 
14 patients did not receive their allocated intervention after being randomised. There were 
also some cases of incomplete compliance with treatment. The ability to bear weight 
immediately within a functional brace may have triggered the desire to change treatment, 
given that the majority changed from the Plaster Cast group to the Functional Bracing group. 
However, the overall number is small in a trial of this size and the CACE analysis, that is the 
analysis adjusted for incomplete compliance, confirmed the result of the primary analysis i.e. 
there was no evidence of a difference between the two groups of participants at nine months 
post injury. 
Loss to follow-up is another potential limitation. However, over 93% of participants provided 
primary outcome data at nine months, which is considerably higher than the 80% assumed in 
the trial design. Therefore, given that the trial also exceeded the minimum sample size by 
some margin, we can be confident that the conclusions are robust and the risk of type II error 
is very low. 
6. Conclusions  
This trial provides strong evidence that early weight-bearing in a functional brace provides 
similar outcomes to traditional plaster casting and is safe for patients having non-operative 
treatment of an Achilles tendon rupture. The use of functional bracing is very likely to be 
cost-effective. 
While the UKSTAR trial provides guidance with regard to the early management of patients, 
rehabilitation following an Achilles tendon rupture is prolonged and further research is 
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7.3 Recruitment Centres 
Table 24: Principal Investigators by recruitment centre  
NHS Trust name Principal Investigator 
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NHS Trust 
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Salisbury District Hospital Sridhar Sampalli 
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Rotherham Hospital Sandeep Kapoor 
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Appendix 1: Trial management 
Introduction 
The UKSTAR Trial completed recruitment on schedule (Figure 14), recruiting 540 
participants. 
 
Figure 14: UKSTAR actual and predicted recruitment 
 
Completeness of baseline and 8-week data, and rates of follow-up at all time-points were 
excellent, thanks to the dedication of clinicians and researchers at the recruitment centres and 
an experienced, dedicated, central trial management team. 
Management milestones 






Table 25: Progress against milestones in Project Management Plan 
Event Planned date Actual date 
Grant activation 1st April 2016 1st April 2016 
Trial open 16th August 2016 16th August 2016 
First DSMCa/TSCb meeting 6th July 2016 6th July 2016 
Expected end of recruitment 31st May 2018 31st May 2018 
Expected end of follow-up 31st March 2019 12th March 2019 
Expected start of data cleaning January 2019 January 2019 
Expected start of final analysis March 2019 March 2019 
End of Grant 31st May 2019 31st May 2019 
a DSMC: Data Safety and Monitoring Committee; b TSC: Trial Steering Committee 
 
Recruitment target and recruitment centre selection 
Principal Investigators at potential recruitment centres were approached through the 
NIHR/Orthopaedic Trauma Society Research Network and British Foot and Ankle Society. 
We included sites from regions across England and Scotland, of all sizes from Major Trauma 
Centres to Local Emergency Hospitals. 
Each potential recruitment centre completed a Site Feasibility Questionnaire, which was 
reviewed by the Chief Investigator. Sites were asked to declare how many patients presented 
at their site with Achilles tendon rupture and were treated non-operatively, and their expected 
recruitment rate, which needed to be at least 1 participant per month. Some sites declined on 
the grounds that their patients were already all put into a functional brace, or were all treated 
with a plaster cast. Sites which were actively recruiting for another Achilles trial in our research 
group, the PATH-2 study, were not opened to UKSTAR until after recruitment for PATH-2 




The UKSTAR trial opened to recruitment on 16th August 2016, one month later than planned 
due to contractual delays at recruitment centres. The original application predicted a 
recruitment rate of 1 participant per month per centre, which led to the conclusion that a 
minimum of 22 centres was required. However, during the first six months, although more 
recruitment centres were opened than planned (nine as opposed to six), recruitment in most 
was slower than expected (27 participants in total) and weighted towards a single, high-
recruiting recruitment centre (15 participants at Aberdeen). We decided therefore to expand the 
number of recruitment centres and were successful in opening 39 recruitment centres, including 
some whose Trauma departments were new to trials. 
One recruitment centre (James Paget, Norfolk) closed to recruitment early due to lack of 
research staff, having recruited no participants. All other recruitment centres recruited at least 
one participant. 
The trial reached its original recruitment target of 330 participants in October 2017, seven 
months ahead of target. For 90% power in the primary outcome (ATRS at 9 months) and 
allowing for 20% loss to follow-up and crossovers, a sample size of 330 participants was 
required. In September 2017, when it became apparent that the target would soon be reached, 
there was doubt over the quantity and quality of data being collected. Some patients were 
unhappy with their allocation and crossed over to the other group of the trial. In addition, as 
few participants by then had reached the nine month time-point, which was the primary 
outcome, we could not be sure how many of the cohort would remain engaged with the trial up 
to the nine month time-point. To avoid the power of the trial being compromised by high 
numbers of crossovers and loss to follow-up at nine months, we submitted a substantial 
amendment to increase the sample size to a maximum of 550, and to recruit up to the original 
recruitment end date (31 May 2018). The chairs of the DSMC and TSC ratified this approach 
and the Research Ethics Committee gave a favourable opinion. The trial continued recruiting 
until its original planned end date, recruiting 540 participants (Figure 14: UKSTAR 
actual and predicted recruitment 
). 
Monitoring of trial recruitment 
Recruitment centres were trained in recruitment procedures at Site Initiation Visits, which were 




recruitment centres when staff were experienced in trial recruitment. Recruitment centres 
completed a monthly Screening Log, declaring all patients who had presented to the 
Emergency Department or specialist Fracture Clinic or Foot and Ankle Clinic with Achilles 
tendon rupture. We monitored the reasons for non-recruitment, looking for trends at particular 
recruitment centres, and addressed them on a centre-by-centre basis. Recruitment centres were 
informed of how their recruitment rate compared to that of other recruitment centres in a 
monthly newsletter. 
Data management 
The Data Management Plan (DMP) defined the trial’s data management procedures, in 
accordance with the Trials Unit’s Standard Operating Procedures. The DMP identified 
databases and IT systems used by the trial, defined data types, data sharing and access, the 
critical data items, questionnaires and events, and the location of the trial data matrix; and 
described confidentiality, how protocol deviations were defined and what action to take, how 
source data was collected and entered at each time-point, and how follow-up was managed. It 
recorded decisions on follow-up time windows made by TMG, data rulings made by Chief 
Investigator, Statistician, Health Economist or Trial Manager, how data queries were handled 
and how data would be processed at the end of the trial.  
The trial Monitoring Plan described procedures for central monitoring, and stated that no site 
monitoring would take place unless triggered by concerns. All recruitment centres were 
monitored centrally and none generated concerns sufficient to merit a monitoring visit. 
Trial promotion 
Promotion to patients and the public 
A public-facing web page hosted within the OCTRU trials unit web pages held trial 
information, current recruitment figures and news. 
Promotion within the Trauma and scientific communities 
The UKSTAR trial was featured on a poster at the 7th NIHR OTS Musculoskeletal Trauma 
Trials Annual Meeting on 9th January 2019. The Kadoorie Centre newsletter, sent to 
recruitment centres participating in Oxford Trauma trials, highlighted the end of follow-up 
and excellent retention rate in its March 2019 issue. A regular monthly newsletter was sent to 
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recruitment centres during recruitment to help maintain engagement and to acknowledge and 





Appendix 2: Site Names by NHS Trust 
Table 26. Site Names by NHS Trust  
Trial center  Trust Name 
          ABD Aberdeen Royal Infirmary, NHS Grampian 
          AIR Airedale NHS Foundation Trust, Keighley 
          BRT Queen’s Hospital, Burton Hospitals NHS Foundation Trust 
          CHX St Mary’s Hospital, Imperial College Healthcare NHS Trust London 
          CUH Addenbrookes Hospital, Cambridge University Hospital NHS Foundation Trust 
          DBH Doncaster Royal Infirmary, Doncaster & Bassetlaw Hospitals NHS Foundation Trust 
          DUN Ninewells Hospital and Medical School, NHS Tayside, Dundee 
          ENH Lister Hospital, East and North Herts NHS Foundation Trust 
          GEH George Eliot Hospital NHS Foundation Trust, Nuneaton 
          GLA Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde 
          HCH Hereford County Hospital, Wye Valley NHS Trust 
          HEY Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust 
          INV Raigmore Hospital, Inverness, NHS Highland 
          KCH  King’s College Hospital NHS Foundation Trust, London 
          LDH  Luton and Dunstable University Hospital 
          LDS  Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust 
 MKN Milton Keynes University Hospital NHS Foundation Trust 
          MPH Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust 
MTW Tunbridge Wells Hospital, Maidstone & Tunbridge Wells NHS Trust 
          MYH Pinderfields Hospital, Mid Yorkshire NHS Trust 
          NLG Scunthorpe General Hospital, Northern Lincolnshire and Goole NHS Foundation Trust 
          NTE 




          NUH Nottingham University Hospitals NHS Trust 
          OUH John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust 
          PLY Derriford Hospital, University Hospitals Plymouth NHS Trust 
          QEH Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust 
          RBK Royal Berkshire Hospital, Royal Berkshire NHS Foundation Trust 
          RCH Royal Cornwall Hospital, Truro, Royal Cornwall Hospitals NHS Trust 
          RED Worcestershire Royal Hospital, Worcester Acute Hospitals NHS Trust 
          RTH  The Rotherham NHS Foundation Trust 
          SAL  Salisbury District Hospital, Salisbury NHS Foundation Trust 
          SHC St Helier Hospital, Epsom and St Helier University Hospitals NHS Trust 
          SLF Salford Royal NHS Foundation Trust 
          UHS 
Southampton General Hospital, University Hospital Southampton NHS Foundation 
Trust 
          ULH Pilgrim Hospital, Boston, United Lincolnshire Hospitals NHS Trust 
WAR  Warwick Hospital, South Warwickshire NHS Foundation Trust 
          WHI Whiston Hospital, Warrington, St Helens & Knowsley Teaching Hospital NHS Trust 





Appendix 3: EQ-5D Individual Level Items 
 
Figure 15: EQ-5D Mobility from baseline pre-injury to 9 months. EQ-5D Mobility values 
range from 1 to 5 with 1 indicating no problems 
 
Figure 16: EQ-5D Self Care from baseline pre-injury to 9 months. EQ-5D Self Care values 





Figure 17: EQ-5D Usual Activities from baseline pre-injury to 9 months. EQ-5D Usual 
Activities values range from 1 to 5 with 1 indicating no problems 
 
 
Figure 18: EQ-5D Pain Discomfort from baseline pre-injury to 9 months. EQ-5D Pain 







Figure 19: EQ-5D Anxiety Depression from baseline pre-injury to 9 months. EQ-5D Anxiety 




Appendix 4: Health Economics  
 
 
Table 27: Summary of unit cost data and data sources 
Resource item  Unit cost1 Unit of analysis  Source of unit cost 
Outpatient care  
Speciality: Orthopaedics £121.30 per visit NHS reference costs 2016-17 51 
Speciality: Pathology £114.03 per visit NHS reference costs 2016-17 51 
Speciality: Radiology £47.78 per visit NHS reference costs 2016-17 51 
Speciality: Physiotherapy (NHS) £48.81 per visit NHS reference costs 2016-17 51 
Speciality: Physiotherapy 
(Private) 




£147.80 per visit NHS reference costs 2016-17 51 
Primary and community care  
General practitioner consultations  
in surgery 
£4.00 per minute contact PSSRU 2018 42 
General practitioner home visits £4.00 per minute contact PSSRU 2018 42 
General practitioner telephone 
contacts 
£3.80 per 1min telephone 
consultation lasting 7.1 
min 
PSSRU 2015 57 
Practice nurse contacts £0.53 minute  PSSRU 2018 42 
District nurse contacts £0.97 per minute of patient-
related work  
PSSRU 2018 42 
Community physiotherapy 
contacts 
£0.87 Per minute of patient-
related work 
PSSRU 2018 42 
Calls to NHS direct/111 £8.00 per call Turner et al. 2012 58 
Calls for an ambulance or 
paramedic 
£7.21 per call 
 




Personal Social Services 





.pdf, last accessed 5 June 2019) 





.pdf, last accessed 5 June 2019) 
Laundry services £4.52 per load North Yorkshire social care 
Social worker contacts £48.00 per visit PSSRU 2017, pg 94 59 
Care worker contacts including 
help at home 
£0.43 per min PSSRU 2017, pg 125 59 
Other: 
   
Aids and Adaptations 
Crutches £5.61 per item NHS Catalogue 2018 46 
Stick £3.98 per item NHS Catalogue 2018 46 
Zimmer frame £37.70 per item NHS Catalogue 2018 46 
Grab rail £5.03 per item NHS Catalogue 2018 46 
Dressing aids £4.42 per item NHS Catalogue 2018 46 
Long-handle shoe horn £1.78 per item NHS Catalogue 2018 46 
Productivity losses 
   
Days off work £90.90 per day Office for National Statistics 47 
1When appropriate, costs were inflated or deflated to 2017–18 prices using the Hospital and Community Health 
Services (HCHS) Pay and Price Inflation 
PSSRU: Personal Social Services Research Unit
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Table 28: Use of health and social care resources related to two non-surgical treatment 
options for patients with a primary (first-time) rupture of the Achilles tendon by each follow-
up period and treatment arm (complete cases) 






(Bootstrapped 95% CI)  
p-value1 
8-week follow-up  
    
Inpatient Care Mean length of stay in days (SE)   
Hospital stay 0.035 (0.018) 0.071 (0.032) -0.036 (-0.110 to 0.028) 0.323 
  
 Proportion of participants 
prescribed anticoagulant as VTE 
prophylaxis treatment  (SE)  
 
Anticoagulant treatment 0.716 (0.028) 0.594 (0.030) 0.122 (0.032 to 0.200) 0.003 
     
Outpatient care Mean no. of visits (SE)   
Orthopaedics 2.627 (0.107) 1.800 (0.097) 0.827 (0.574 to 1.119) P<0.001 
Pathology 0.041 (0.014) 0.068 (0.023) -0.027 (-0.084 to 0.025) 0.325 
Radiology 0.150 (0.023) 0.146 (0.029) 0.004 (-0.070 to 0.074) 0.907 
Physiotherapy NHS 0.228 (0.042) 0.460 (0.064) -0.232 (-0.397 to -0.095) 0.003 
Physiotherapy Private 0.091 (0.037) 0.184 (0.160) -0.093 (-0.575 to 0.117) 0.576 
Emergency Department (Injury –related) 0.104 (0.023) 0.096 (0.021) 0.008 (-0.051 to 0.070) 0.804 
Emergency Department (other reasons) 0.029 (0.012) 0.016 (0.008) 0.013 (-0.012 to 0.044) 0.371 
Other  0.111 (0.037) 0.168 (0.045) -0.058 (-0.162 to 0.062) 0.326 
     










(Bootstrapped 95% CI)  
p-value1 
GP Visits (surgery) 0.100 (0.024) 0.188 (0.032) -0.088 (-0.176 to -0.012) 0.028 
GP (home visits) 0.008 (0.006) 0 (0) 0.008 (0 to 0.024) 0.148 
GP (telephone contacts) 0.084 (0.025) 0.108 (0.031) -0.024 (-0.103 to 0.049) 0.542 
Practice nurse contacts 0.008 (0.006) 0.008 (0.006) 0 (-0.015 to 0.018) 0.964 
District nurse contacts 0.151 (0.146) 0 (0) 0.151 (0 to 0.553) 0.293 
Community physiotherapy contacts 0.021 (0.013) 0.040 (0.020) -0.019 (-0.074 to 0.020) 0.429 
Calls to NHS direct 0.017 (0.010) 0.008 (0.008) 0.009 (-0.012 to 0.039) 0.499 
Calls for an ambulance or paramedic 0.004 (0.004) 0 (0) 0.004 (0 to 0.017) 0.307 
Occupational therapy contacts 0.013 (0.009) 0.008 (0.006) 0.005 (-0.012 to 0.034) 0.673 
Other 0.216 (0.146) 0.034 (0.015) 0.183 (-0.010 to 0.580) 0.206 
     
Medicines  Proportion of participants 
prescribed each class of drug (SE) 
  
Analgesics 0.388 (0.055) 0.330 (0.050) 0.058 (-0.083 to 0.213) 0.434 
Anti-inflammatories 0.042 (0.013) 0.076 (0.017) -0.034 (-0.081 to 0.004) 0.110 
Anti-coagulant 0.151 (0.023) 0.112 (0.020) 0.039 (-0.026 to 0.093) 0.206 
Other  0.017 (0.008) 0.048 (0.014) -0.031 (-0.064 to -0.001) 0.052 
     
Aids and adaptations Mean count (SE)   
Crutches 1.290 (0.059) 1.124 (0.062) 0.166 (0.012 to 0.341) 0.053 
Stick 0.017 (0.010) 0.024 (0.010) -0.007 (-0.033 to 0.024) 0.598 
Zimmer frame 0.054 (0.018) 0.028 (0.010) 0.026 (-0.014 to 0.068) 0.205 
Grab Rail  0.046 (0.020) 0 (0) 0.046 (0.013 to 0.090) 0.019 
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(Bootstrapped 95% CI)  
p-value1 
Dressing aids 0.008 (0.008) 0.008 (0.006) 0 (-0.016 to 0.024) 0.976 
Long-handle shoe horn  0.004 (0.004) 0 (0) 0.004 (0 to 0.016) 0.309 
Other  0.387 (0.045) 0.220 (0.043) 0.166 (0.040 to 0.277) 0.008 
     
Personal social services No. of contacts (SE)   
Frozen meals on wheels 0 0 - - 
Hot meals on wheels 0 0 - - 
Laundry services 0.029 (0.029) 0 (0) 0.029 (0 to 0.095) 0.309 
Social worker contacts 0 0 - - 
Care worker/home help 0.668 (0.542) 0 (0) 0.668 (0 to 2.165) 0.210 
Other  0 0 - - 
     
Productivity losses Mean days off work (SE)    
Days off work 21.227 (1.682) 20.786 (1.637) 0.441 (-3.947 to 5.176) 0.851 
     
Three-month follow-up     
Inpatient Care Mean length of stay in days (SE)   
Hospital stay  0.009 (0.009) 0 (0) 0.009 (0 to 0.034) 0.298 
  
    
Outpatient care Mean no. of visits (SE)   
Orthopaedics 0.428 (0.055) 0.318 (0.045) 0.110 (-0.035 to 0.256) 0.121 










(Bootstrapped 95% CI)  
p-value1 
Radiology 0.057 (0.020) 0.045 (0.017) 0.012 (-0.038 to 0.062) 0.644 
Physiotherapy NHS 0.978 (0.070) 0.959 (0.067) 0.019 (-0.175 to 0.180) 0.845 
Physiotherapy Private 0.271 (0.073) 0.180 (0.045) 0.091 (-0.069 to 0.279) 0.283 
Emergency Department (Injury –related) 0.061 (0.022) 0.033 (0.011) 0.028 (-0.013 to 0.085) 0.241 
Emergency Department (other reasons) 0.009 (0.006) 0.004 (0.004) 0.005 (-0.008 to 0.023) 0.524 
Other  0.057 (0.018) 0.050 (0.024) 0.007 (-0.057 to 0.062) 0.817 
     
Community health care Mean no. of contacts (SE)   
GP Visits (surgery) 0.088 (0.022) 0.107 (0.029) -0.019 (-0.099 to 0.057) 0.610 
GP (home visits) 0 (0) (0) - - 
GP (telephone contacts) 0.044 (0.017) 0.029 (0.013) 0.015 (-0.026 to 0.057) 0.487 
Practice nurse contacts 0.004 (0.004) 0.008 (0.008) -0.004 (-0.026 to 0.009) 0.689 
District nurse contacts 0.004 (0.004) 0.004 (0.004) 0 (-0.011 to 0.013) 0.964 
Community physiotherapy contacts 0.253 (0.065) 0.201 (0.044) 0.052 (-0.085 to 0.223) 0.500 
Calls to NHS direct 0.004 (0.004) 0.004 (0.004) 0 (-0.009 to 0.013) 0.964 
Calls for an ambulance or paramedic 0.013 (0.010) 0.004 (0.004) 0.009 (-0.008 to 0.036) 0.385 
Occupational therapy contacts 0.022 (0.014) 0.049 (0.027) -0.027 (-0.096 to 0.022) 0.382 
Other 0.061 (0.032) 0.021 (0.012) 0.041 (-0.017 to 0.122) 0.226 
     
Medicines  Proportion of participants 
prescribed each class of drug (SE) 
  
Analgesics 0.109 (0.021) 0.049 (0.014) 0.060 (0.014 to 0.111) 0.015 
Anti-inflammatories 0.008 (0.006) 0.008 (0.006) 0.001 (-0.015 to 0.019) 0.949 
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(Bootstrapped 95% CI)  
p-value1 
Anti-coagulant 0.022 (0.010) 0.016 (0.008) 0.005 (-0.019 to 0.031) 0.665 
Other  0.017 (0.009) 0 (0) 0.017 (0.004 to 0.039) 0.038 
     
Aids and adaptations Mean count (SE)   
Crutches 0.118 (0.030) 0.106 (0.029) 0.012 (-0.071 to 0.100) 0.778 
Stick 0.070 (0.20) 0.033 (0.014) 0.037 (-0.009 to 0.086) 0.124 
Zimmer frame 0 (0) 0.004 (0.004) 0.004 (-0.016 to 0) 0.335 
Grab Rail  0.022 (0.013) 0 (0) 0.022 (0 to 0.055) 0.084 
Dressing aids 0.031 (0.020) 0 (0) 0.031 (0.004 to 0.083) 0.112 
Long-handle shoe horn  0.013 (0.008) 0 (0) 0.013 (0 to 0.032) 0.073 
Other  0.227 (0.064) 0.155 (0.038) 0.072 (-0.056 to 0.244) 0.330 
     
Personal social services (PSS) No. of contacts (SE)   
Frozen meals on wheels 0 (0) 0 (0) - - 
Hot meals on wheels 0 (0) 0 (0) - - 
Laundry services 0 (0) 0.008 (0.008) -0.008 (-0.033 to 0) 0.333 
Social worker contacts 0 (0) 0 (0) - - 
Care worker/home help 0 (0) 0 (0) - - 
Other  0.009 (0.009) 0 (0) 0.009 (0 to 0.029) 0.301 
     
     
Productivity losses No. of days off work    










(Bootstrapped 95% CI)  
p-value1 
     
     
Six-month follow-up     
Subsequent Inpatient Care Mean length of stay in days (SE)   
Hospital stay  0 (0) 0 (0) - - 
  
    
Outpatient care Mean no. of visits (SE)   
Orthopaedics 0.224 (0.043) 0.289 (0.059) -0.065 (-0.230 to 0.071) 0.379 
Pathology 0.018 (0.011) 0.030 (0.015) -0.012 (-0.048 to 0.024) 0.532 
Radiology 0.044 (0.015) 0.033 (0.012) 0.011 (-0.027 to 0.050) 0.564 
Physiotherapy NHS 1.946 (0.257) 1.915 (0.182) 0.031 (-0.550 to 0.674) 0.920 
Physiotherapy Private 0.417 (0.103) 0.366 (0.091) 0.051 (-0.218 to 0.316) 0.710 
Emergency Department (Injury –related) 0.013 (0.008) 0.026 (0.010) -0.012 (-0.039 to 0.014) 0.353 
Emergency Department (other reasons) 0.013 (0.008) 0.017 (0.008) -0.004 (-0.026 to 0.018) 0.756 
Other  0.093 (0.031) 0.067 (0.031) 0.026 (-0.065 to 0.103) 0.551 
     
Community health care Mean no. of contacts (SE)   
GP Visits (surgery) 0.094 (0.037) 0.060 (0.018) 0.035 (-0.034 to 0.122) 0.390 
GP (home visits) 0 (0) 0.009 (0.009) -0.009 (-0.028 to 0) 0.331 
GP (telephone contacts) 0.018 (0.011) 0.021 (0.015) -0.003 (-0.046 to 0.031) 0.861 
Practice nurse contacts 0 (0) 0.004 (0.004) -0.004 (-0.017 to 0) 0.331 
District nurse contacts 0 (0) 0 (0) - - 
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(Bootstrapped 95% CI)  
p-value1 
Community physiotherapy contacts 0.605 (0.187) 0.557 (0.101) 0.048 (-0.311 to 0.547) 0.819 
Calls to NHS direct 0 (0) 0 (0) - - 
Calls for an ambulance or paramedic 0 (0) 0 (0) - - 
Occupational therapy contacts 0.067 (0.033) 0.043 (0.023) 0.025 (-0.054 to 0.115) 0.537 
Other 0.058 (0.043) 0.106 (0.077) -0.048 (-0.264 to 0.085) 0.589 
     
Medicines  Proportion of participants 
prescribed each class of drug (SE) 
  
Analgesics 0.103 (0.020) 0.064 (0.016) 0.040 (-0.008 to 0.090) 0.124 
Anti-inflammatories 0.009 (0.006) 0.021 (0.009) -0.012 (-0.036 to 0.009) 0.286 
Anti-coagulant 0.004 (0.004) 0.013 (0.007) -0.008 (-0.025 to 0.009) 0.343 
Other  0.009 (0.006) 0.008 (0.006) 0 (-0.013 to 0.019) 0.955 
     
Aids and adaptations Mean count (SE)   
Crutches 0.054 (0.021) 0.051 (0.020) 0.003 (-0.051 to 0.066) 0.917 
Stick 0.031 (0.012) 0.030 (0.015) 0.002 (-0.041 to 0.035) 0.929 
Zimmer frame 0.009 (0.009) 0.013 (0.007) -0.004 (-0.022) 0.742 
Grab Rail  0.018 (0.011) 0.008 (0.008) 0.009 (-0.013 to 0.038) 0.495 
Dressing aids 0 (0) 0 (0) - - 
Long-handle shoe horn  0.018 (0.009) 0.008 (0.006) 0.009 (-0.009 to 0.032) 0.376 
Other  0.144 (0.047) 0.091 (0.030) 0.054 (-0.031 to 0.188) 0.329 
     










(Bootstrapped 95% CI)  
p-value1 
Frozen meals on wheels 0 (0) 0 (0) - - 
Hot meals on wheels 0 (0) 0 (0) - - 
Laundry services 0 (0) 0 (0) - - 
Social worker contacts 0 (0) 0 (0) - - 
Care worker/home help 0.036 (0.036) 0 (0) 0.036 (0 to 0.138)  
Other  0 (0) 0 (0) - - 
     
Productivity losses No. of days off work    
Days off work 1.894 (0.743) 4.301 (1.172) -2.407 (-5.642 to -0.110) 0.085 
     
     
Nine-month follow-up     
Subsequent Inpatient Care Mean length of stay in days (SE)   
Hospital stay  0 (0) 0 (0) - - 
     
  
    
Outpatient care Mean no. of visits (SE)   
Orthopaedics 0.090 (0.024) 0.077 (0.030) 0.013 (-0.060 to 0.081) 0.736 
Pathology 0.016 (0.008) 0.073 (0.027) -0.057 (-0.120 to -0.012) 0.047 
Radiology 0.029 (0.011) 0.012 (0.009) 0.017 (-0.005 to 0.047) 0.209 
Physiotherapy NHS 0.709 (0.108) 0.857 (0.147) -0.148 (-0.540 to 0.178) 0.423 
Physiotherapy Private 0.234 (0.073) 0.174 (0.058) 0.060 (-0.103 to 0.260) 0.520 
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(Bootstrapped 95% CI)  
p-value1 
Emergency Department (injury –related) 0.004 (0.004) 0.008 (0.005) -0.004 (-0.016 to 0.012) 0.599 
Emergency Department (other reasons) 0.020 (0.011) 0.030 (0.014) -0.010 (-0.051 to 0.019) 0.566 
Other  0.140 (0.058) 0.089 (0.045) 0.051 (-0.090 to 0.206) 0.487 
     
Community health care Mean no. of contacts (SE)   
GP Visits (surgery) 0.058 (0.024) 0.046 (0.017) 0.011 (-0.046 to 0.072) 0.697 
GP (home visits) 0 (0) 0 (0) - - 
GP (telephone contacts) 0.008 (0.006) 0.004 (0.004) 0.004 (-0.007 to 0.021) 0.527 
Practice nurse contacts 0 (0) 0.004 (0.004) -0.004 (-0.016 to 0) 0.333 
District nurse contacts 0 (0) 0 (0) - - 
Community physiotherapy contacts 0.169 (0.052) 0.255 (0.066) -0.085 (-0.258 to 0.071) 0.317 
Calls to NHS direct 0 (0) 0 (0) - - 
Calls for an ambulance or paramedic 0 (0) 0 (0) - - 
Occupational therapy contacts 0.074 (0.038) 0.031 (0.017) 0.043 (-0.033 to 0.128) 0.291 
Other 0.136 (0.070) 0.131 (0.100) 0.005 (-0.307 to 0.214) 0.967 
     
Medicines  Proportion of participants 
prescribed each class of drug (SE) 
  
Analgesics 0.037 (0.012) 0.031 (0.011) 0.006 (-0.027 to 0.037) 0.703 
Anti-inflammatories 0.012 (0.007) 0 (0) 0.012 (0 to 0.029) 0.073 
Anti-coagulant 0.004 (0.004) 0 (0) 0.004 (0 to 0.016) 0.301 
Other  0.004 (0.004) 0.004 (0.004) 0 (-0.008 to 0.016) 0.964 










(Bootstrapped 95% CI)  
p-value1 
Aids and adaptations Mean count (SE)   
Crutches 0 (0) 0.008 (0.008) -0.008 (-0.029 to 0) 0.334 
Stick 0.012 (0.009) 0.004 (0.004) 0.009 (-0.008 to 0.036) 0.383 
Zimmer frame 0 (0) 0 (0) - - 
Grab Rail  0.008 (0.008) 0 (0) 0.008 (0 to 0.031) 0.301 
Dressing aids 0 (0) 0 (0) - - 
Long-handle shoe horn  0.004 (0.004) 0 (0) 0.004 (0 to 0.017) 0.301 
Other  0.062 (0.025) 0.093 (0.026) -0.031 (-0.097 to 0.046) 0.397 
     
Personal social services No. of contacts (SE)   
Frozen meals on wheels 0.045 (0.045) 0 (0) 0.045 (0 to 0.182) 0.301 
Hot meals on wheels 0 (0) 0 (0) - - 
Laundry services 0.045 (0.045) 0 (0) 0.045 (0 to 0.182) 0.301 
Social worker contacts 0 (0) 0 (0) - - 
Care worker/home help 0.008 (0.008) 0 (0) 0.008 (0 to 0.037) 0.301 
Other  0 (0) 0 (0) - - 
     
     
Productivity losses No. of days off work    
Days off work 0.340 (0.340) 1.952 (0.758) -1.613 (-3.357 to 0.019) 0.055 
1Comparisons of Plaster Cast vs Functional Brace groups carried out using Student t-tests for continuous variables and χ2 test 
for categorical variables. 
B GP: general practitioner 
